<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cystic fibrosis: Overview of the treatment of lung disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cystic fibrosis: Overview of the treatment of lung disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cystic fibrosis: Overview of the treatment of lung disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Simon, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James F Chmiel, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cystic fibrosis (CF) is a multisystem disorder caused by pathogenic mutations of the <em>CFTR</em> gene (CF transmembrane conductance regulator). Pulmonary disease remains the leading cause of morbidity and mortality in patients with CF. (See  <a class="medical medical_review" href="/d/html/6368.html" rel="external">"Cystic fibrosis: Genetics and pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/6367.html" rel="external">"Cystic fibrosis: Clinical manifestations and diagnosis"</a>.)</p><p>The treatment of CF lung disease is experiencing a period of rapid evolution, supported by well-designed clinical trials and improved understanding of the genetics and pathophysiology of the disease [<a href="#rid1">1</a>]. Undoubtedly, these advancements are responsible for a substantial portion of the improvement that has occurred in patient survival, which has been accelerated by the introduction of the highly effective CFTR modulator combination <a class="drug drug_general" data-topicid="122968" href="/d/drug information/122968.html" rel="external">elexacaftor-tezacaftor-ivacaftor</a> (ETI)  (<a class="graphic graphic_figure graphicRef61930" href="/d/graphic/61930.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/118899.html" rel="external">"Cystic fibrosis: Treatment with CFTR modulators"</a>.)</p><p>The focus of this discussion is on pulmonary therapies for patients meeting diagnostic criteria for CF. Although it has been traditionally thought that there are no clinical consequences from being heterozygous for a <em>CFTR</em> disease-causing mutation, studies using large databases have shown that these individuals are at an increased risk for developing a variety of CF-related manifestations [<a href="#rid2">2-4</a>]. However, there is insufficient information to extrapolate CF-specific treatments to those who do not meet diagnostic criteria for CF. (See  <a class="medical medical_review" href="/d/html/6367.html" rel="external">"Cystic fibrosis: Clinical manifestations and diagnosis"</a>.)</p><p>CF is a multisystem disease. Sinus infection, nutritional status, glucose control, and psychosocial issues must all be assessed at regular intervals. This requires a multidisciplinary approach to care. In the United States, such care is provided at one of more than 120 CF care centers that are supported and accredited by the Cystic Fibrosis Foundation (CFF), most of which have dedicated programs for both children and adults. Patients treated at these centers are seen on a regular basis by clinicians, nurses, dietitians, respiratory therapists, physical therapists, and social workers with special competence in CF care. A listing of these centers is available on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fapps.cff.org%2Fccd%2F&amp;token=iZ96OWSp58r0YACVRdCkzQnUT8%2FObe%2FNp0jveDLvRCDR%2FR9VRSHwAVxFWiSJMbOc&amp;TOPIC_ID=6372" target="_blank">CFF website</a>. In the United Kingdom, CF patients receiving their medical care at specialized CF centers have better clinical outcomes compared with patients receiving care in less specialized settings [<a href="#rid5">5-7</a>]. In the United States, more frequent clinician-patient interaction (visit frequency, monitoring, and interventions for pulmonary exacerbations) is associated with improved outcomes [<a href="#rid8">8</a>].</p><p>An overview of the treatment of CF lung disease will be presented here; the main strategies are outlined in the table  (<a class="graphic graphic_table graphicRef119343" href="/d/graphic/119343.html" rel="external">table 1</a>). Other aspects of CF-associated lung disease are discussed in the following topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6369.html" rel="external">"Cystic fibrosis: Clinical manifestations of pulmonary disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/110933.html" rel="external">"Cystic fibrosis: Management of pulmonary exacerbations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/140721.html" rel="external">"Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/118899.html" rel="external">"Cystic fibrosis: Treatment with CFTR modulators"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/129117.html" rel="external">"Cystic fibrosis: Management of advanced lung disease"</a>.)</p><p></p><p>The diagnosis and pathophysiology of CF and its manifestations in other organ systems are also discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6367.html" rel="external">"Cystic fibrosis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6368.html" rel="external">"Cystic fibrosis: Genetics and pathogenesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14544.html" rel="external">"Cystic fibrosis-related diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5858.html" rel="external">"Cystic fibrosis: Overview of gastrointestinal disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5885.html" rel="external">"Cystic fibrosis: Assessment and management of pancreatic insufficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5882.html" rel="external">"Cystic fibrosis: Nutritional issues"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/99126.html" rel="external">"Cystic fibrosis: Hepatobiliary disease"</a>.)</p><p></p><p class="headingAnchor" id="H1582720784"><span class="h1">CHRONIC MEASURES TO PROMOTE LUNG HEALTH</span><span class="headingEndMark"> — </span>Medical therapies to manage CF lung disease are summarized in the table  (<a class="graphic graphic_table graphicRef119343" href="/d/graphic/119343.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H2546937538"><span class="h2">CFTR modulators</span><span class="headingEndMark"> — </span>CF transmembrane conductance regulator (CFTR) modulators are a new class of drugs that act by improving production, intracellular processing, and/or function of the defective CFTR protein. All CF patients should undergo <em>CFTR</em> genotyping to determine if they carry a mutation that makes them eligible for CFTR modulator therapy, which include F508del and many other mutations  (<a class="graphic graphic_table graphicRef130494" href="/d/graphic/130494.html" rel="external">table 2</a>). Selection of the CFTR modulator depends on the <em>CFTR</em> mutation and the patient's age, as outlined in the algorithms  (<a class="graphic graphic_algorithm graphicRef130531" href="/d/graphic/130531.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef130532" href="/d/graphic/130532.html" rel="external">algorithm 2</a>).</p><p>Details of patient selection and summaries of clinical outcomes for CFTR modulators are presented in a separate topic review. (See  <a class="medical medical_review" href="/d/html/118899.html" rel="external">"Cystic fibrosis: Treatment with CFTR modulators"</a>.)</p><p class="headingAnchor" id="H1441570215"><span class="h2">Airway clearance therapies</span><span class="headingEndMark"> — </span>Difficulty clearing secretions from the airways is a common complaint among CF patients who have moderate to severe lung disease. The high viscosity of CF sputum is caused by its relative dehydration and the interaction of several macromolecules, including mucus glycoproteins, denatured deoxyribonucleic acid (DNA), and protein polymers such as actin filaments [<a href="#rid1">1,9,10</a>]. Airway clearance can be promoted by a combination of inhaled drugs to loosen and liquefy the inspissated mucus (dornase alfa [<a class="drug drug_general" data-topicid="9385" href="/d/drug information/9385.html" rel="external">DNase</a>], hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, and/or <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a>) and physical means to dislodge and help the patient expectorate the secretions (breathing/coughing maneuvers, oscillating positive expiratory pressure [PEP] devices, percussive vests), typically administered in two or more sessions daily.</p><p>The highly effective CFTR modulator <a class="drug drug_general" data-topicid="122968" href="/d/drug information/122968.html" rel="external">elexacaftor-tezacaftor-ivacaftor</a> (ETI) substantially reduces sputum production and mucus plugging [<a href="#rid11">11,12</a>], such that at least 50 percent of patients taking ETI no longer expectorate sputum. These observations, together with results from a large clinical trial (SIMPLIFY study, described below), have modified our suggested approach to airway clearance therapies.</p><p class="headingAnchor" id="H1748386731"><span class="h3">Inhaled airway clearance agents</span><span class="headingEndMark"> — </span>Inhaled <a class="drug drug_general" data-topicid="9385" href="/d/drug information/9385.html" rel="external">DNase</a> and hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> have been recommended for most CF patients to promote airway clearance, as outlined in CFF guidelines [<a href="#rid13">13-15</a>]. However, these guidelines were written prior to the approval and widespread use of ETI and subsequent clinical experience and evidence from a large randomized study (SIMPLIFY study [<a href="#rid16">16</a>], described below) that suggests that these inhaled therapies may not be necessary for some patients. It is also noteworthy that the effectiveness of inhaled medications is often compromised because many patients do not adhere to recommended airway clearance therapies, due to treatment burden (time, cost of DNase) and/or tolerability [<a href="#rid3">3</a>].</p><p>Therefore, we suggest the following approach:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients ≥12 years on ETI with mild or no lung disease </strong>– For this group of patients, we no longer routinely recommend <a class="drug drug_general" data-topicid="9385" href="/d/drug information/9385.html" rel="external">DNase</a> or hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>. This is based on the observation that many people with CF no longer expectorate sputum after starting ETI [<a href="#rid11">11</a>] and the results of a prospective randomized trial ("SIMPLIFY") that evaluated the effects of inhaled airway clearance agents in patients on ETI who had mild or no lung disease (percent predicted forced expiratory volume in one second [FEV<sub>1]</sub> &gt;70 for those 12 to 17 years old and &gt;60 for those older than 17 years) [<a href="#rid16">16</a>]. Participants were randomized to continue or stop either their hypertonic saline or DNase for six weeks, after which the clinical consequences were assessed. The absolute change in percent predicted FEV<sub>1 </sub>between baseline and six weeks did not differ between those stopping and those continuing hypertonic saline (between group difference -0.32 percent [95% CI -1.25 to 0.60]) and between those stopping and those continuing DNase (between group difference 0.35 percent [95% CI -0.45 to 1.14]). Lung clearance index (LCI<sub>2.5</sub>), a more sensitive measure of change in lung function in patients with mild lung disease, did not differ between groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other patients</strong> – We recommend both <a class="drug drug_general" data-topicid="9385" href="/d/drug information/9385.html" rel="external">DNase</a> and hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> for the following groups:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients ≥12 years who are on ETI and have moderate to severe lung disease, or those who are not on ETI, regardless of severity of lung disease [<a href="#rid13">13</a>]. This includes those who are on other CFTR modulators (eg, <a class="drug drug_general" data-topicid="17144" href="/d/drug information/17144.html" rel="external">ivacaftor</a> monotherapy or <a class="drug drug_general" data-topicid="116733" href="/d/drug information/116733.html" rel="external">tezacaftor-ivacaftor</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients 6 to 11 years old, including those on ETI. This is because the SIMPLIFY study did not enroll patients younger than 12 years old and we hesitate to extrapolate to this younger group without additional supporting data.</p><p></p><p class="bulletIndent2">Separate CFF guidelines for ages two to five years [<a href="#rid14">14</a>] and less than two years [<a href="#rid15">15</a>] recommend <a class="drug drug_general" data-topicid="9385" href="/d/drug information/9385.html" rel="external">DNase</a> and hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> based on individual circumstances. Our practice is to offer treatment to those with chronic respiratory symptoms or who have more than rare pulmonary exacerbations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agents</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Inhaled </strong><strong>DNase</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9385" href="/d/drug information/9385.html" rel="external">DNase</a> is an endonuclease that decreases the viscosity of purulent CF sputum by cleaving long strands of denatured DNA that are released by degenerating neutrophils, which helps to liquefy CF sputum.</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9385" href="/d/drug information/9385.html" rel="external">DNase</a> is generally given once daily. However, results from a small 12-week crossover trial suggest that alternate-day dosing may achieve equivalent clinical outcomes with substantially lower drug costs [<a href="#rid17">17,18</a>].</p><p></p><p class="bulletIndent2">Evidence for the efficacy of inhaled <a class="drug drug_general" data-topicid="9385" href="/d/drug information/9385.html" rel="external">DNase</a> is from studies performed prior to widespread use of ETI, including a meta-analysis [<a href="#rid19">19</a>], registry study [<a href="#rid20">20</a>], and randomized study of treatment withdrawal [<a href="#rid21">21</a>]. In the meta-analysis, DNase reduced the frequency of pulmonary exacerbations and caused a relative increase in percent predicted FEV<sub>1</sub> by approximately 5 percent in trials extending up to two years [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Inhaled hypertonic </strong><strong>saline</strong> – Inhaled hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> helps to hydrate the inspissated mucus that is present in the airways of patients with CF [<a href="#rid22">22</a>]. It is presumed that the high osmolality of the solutions draws water from the airway to temporarily reestablish the aqueous surface layer that is deficient in CF [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent2">Evidence for the efficacy of hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> is from randomized trials performed prior to widespread use of ETI, which showed that this treatment led to fewer pulmonary exacerbations and improved mucociliary clearance, with no significant effect on pulmonary function [<a href="#rid24">24-28</a>]. Additional evidence supported its use in infants and toddlers (currently not eligible for ETI), based on favorable results from a study that enrolled infants less than four months old [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent2">Inhaled <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> may be used as a second-line option to replace hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> for adult patients with CF who do not tolerate or do not respond well to the combination of <a class="drug drug_general" data-topicid="9385" href="/d/drug information/9385.html" rel="external">DNase</a> and hypertonic saline for airway clearance. Clinical trials of inhaled mannitol found modest improvements in FEV<sub>1</sub>, with little or no improvement in other outcomes such as frequency or duration of exacerbations [<a href="#rid30">30-33</a>]. Although the SIMPLIFY study did not evaluate mannitol, we suspect mannitol's efficacy may be limited in patients on ETI who have normal or mildly reduced FEV<sub>1</sub>, similar to that study’s findings for hypertonic saline [<a href="#rid16">16</a>]. Because inhaled mannitol may cause bronchospasm in patients with bronchial hyperresponsiveness, the initial dose must be administered with spirometry and oxygen saturation monitoring in the presence of an experienced clinician.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – If these inhaled therapies are given, the recommended order of treatments to be performed twice daily is [<a href="#rid13">13</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9396" href="/d/drug information/9396.html" rel="external">Albuterol</a> by metered-dose inhaler (to reduce the risk of bronchospasm) [<a href="#rid24">24</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9385" href="/d/drug information/9385.html" rel="external">DNase</a> (only once a day) and airway clearance therapy (chest physiotherapy)/exercise (in either order) [<a href="#rid34">34</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Other inhaled treatments such as aerosolized antibiotics or long-acting antiasthmatic agents</p><p></p><p class="bulletIndent1">Inhaled medications should not be mixed together in the same nebulizer, because the consequences of doing so are unknown. In particular, <a class="drug drug_general" data-topicid="9385" href="/d/drug information/9385.html" rel="external">DNase</a> is inactivated if it is mixed with hypertonic (7%) <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>. Similarly, these agents should not be mixed with <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a> or other inhaled antibiotics. (See  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Inhaled antibiotics'</a>.)</p><p></p><p class="headingAnchor" id="H3003843164"><span class="h3">Chest physiotherapy</span><span class="headingEndMark"> — </span>Virtually all clinical care guidelines recommend that all patients with CF should be encouraged to use some form of chest physiotherapy for secretion clearance. This recommendation is based on the recognition that retained purulent secretions are an important cause of airflow obstruction and airway injury in CF as well as longstanding clinical practice, despite the lack of strong evidence from clinical trials [<a href="#rid14">14,35-38</a>]. Adherence to chest physiotherapy is often poor, particularly among patients with mild disease [<a href="#rid39">39,40</a>].</p><p>A variety of techniques may be used for chest physiotherapy, and there is no evidence that they differ in efficacy [<a href="#rid37">37,38,41-44</a>]. Because patients vary in their acceptance and preference for different modes, several techniques should be introduced to each patient. Methods that can be performed without assistance from another person should be offered to allow patients to have more control over their regimen. The cost of equipment should be considered, with less expensive modalities prescribed first. A more expensive apparatus such as percussion vests may be appropriate for those patients who fail to clear secretions with less expensive methods, who report that the more expensive modalities are effective for them, and who remain adherent with their use.</p><p>Chest physiotherapy in the form of postural drainage and percussion was introduced to CF care in the 1950s [<a href="#rid35">35,36</a>]. Since then, secretion clearance programs have been a cornerstone of CF care. Methods that can be performed without the aid of another person have largely replaced the traditional technique in older children and adults. These alternatives include a variety of breathing and coughing techniques such as "autogenic drainage," "active cycle of breathing," and "huffing" [<a href="#rid35">35,36,45</a>]. A randomized trial with 36 participants age 12 to 18 years compared autogenic drainage with postural drainage and percussion and reported no difference in pulmonary function test results, but the participants strongly preferred the autogenic drainage modality [<a href="#rid46">46</a>].</p><p>Medical devices of varying cost and complexity have been developed to assist with airway clearance. These include airway oscillating devices, external percussion vests, and intrapulmonary percussive ventilation.</p><p>A systematic review reported that chest physiotherapy (using a variety of techniques) increased mucus transport [<a href="#rid38">38</a>]. Contrasting results were reported from a clinical trial that used gamma scintigraphy to track mucociliary clearance of inhaled small particles, which found that cough plus an external percussive vest, a device inducing oscillatory positive expiratory pressure, or whole-body vibration had no additional benefit compared with cough clearance alone [<a href="#rid37">37</a>].</p><p>Only a few high-quality clinical trials have evaluated the long-term effects of chest physiotherapy. A yearlong randomized trial in 40 participants found that use of a PEP mask significantly improved pulmonary function compared with postural drainage and percussion [<a href="#rid47">47</a>]. The largest study to date randomized 107 participants to use a PEP device or a high-frequency chest wall oscillation device (a percussion vest) for one year [<a href="#rid48">48</a>]. The group using the PEP device experienced significantly fewer pulmonary exacerbations, which was the primary endpoint of the study. No differences were seen in lung function measures, patient satisfaction, or quality-of-life scores. High dropout rates have impaired other attempts at randomized trials, probably because participants often have strong preconceived but unsupported preferences for one treatment arm over another [<a href="#rid49">49,50</a>].</p><p class="headingAnchor" id="H158667531"><span class="h3">Exercise</span><span class="headingEndMark"> — </span>All people with CF should be encouraged to engage in regular exercise to obtain the same benefits that are proven for the general population (see  <a class="medical medical_review" href="/d/html/2786.html" rel="external">"The benefits and risks of aerobic exercise"</a>). Insufficient information is available to determine which types of exercise are most beneficial for people with CF. For those with moderate or advanced pulmonary disease, we advise that exercise should be guided by an organized pulmonary rehabilitation program. (See  <a class="medical medical_review" href="/d/html/1463.html" rel="external">"Pulmonary rehabilitation"</a>.)</p><p>A consensus conference of exercise experts strongly recommended exercise for people with CF [<a href="#rid37">37</a>]. However, the authors recognized that the evidence demonstrating improvement in cardiovascular health and quality of life for people with CF was limited. A meta-analysis concluded that exercise programs lasting at least six months were likely to improve exercise capacity, but the effects on lung function and quality of life were small at best [<a href="#rid51">51</a>].</p><p>In a randomized trial of a three-year home exercise program in children with CF, children assigned to the exercise arm of the study lost less forced vital capacity (FVC) compared with the control group, and Change in FEV<sub>1</sub> showed a similar trend (p&lt;0.07) [<a href="#rid52">52</a>]. In another clinical trial, 41 participants with a mean age of 25 years were randomized to a three-month home exercise program or to continue their usual care. The exercise group showed a statistically significant increase in a maximum strength test but had no improvement in a general measure of quality of life or six-minute walk distance [<a href="#rid53">53</a>]. Another clinical trial randomized 117 adolescents and adults to either three hours per week of vigorous physical exertion or to their usual level of activity [<a href="#rid54">54</a>]. At six months, exercise did not increase FEV<sub>1</sub>, the primary endpoint, but did improve exercise capacity.</p><p>Aerobic exercise may help to mobilize airway secretions, but studies are inconclusive whether it is as effective as therapies directly targeted toward secretion clearance [<a href="#rid55">55,56</a>].</p><p class="headingAnchor" id="H4094483448"><span class="h2">Prevention of infection</span><span class="headingEndMark"> — </span>Measures to prevent pulmonary infection include vaccinations, use of antiviral agents in selected patients, and infection-control measures to prevent transmission of pathogens within health care systems.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinations</strong> – Patients with CF should receive all routine childhood immunizations. Vaccines warranting particular emphasis are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Seasonal influenza vaccine</strong> – Annual vaccination against viral influenza is recommended for all patients with CF older than six months of age, using an inactivated vaccine delivered by injection but not the live attenuated vaccine delivered by intranasal spray [<a href="#rid14">14</a>]. In the United States, annual influenza vaccination is also recommended for healthy children but is particularly important for those with CF or other chronic respiratory diseases. Viral respiratory infections have been implicated as a frequent cause of exacerbations of CF lung disease [<a href="#rid57">57</a>] and are the subject of several reviews [<a href="#rid15">15,58,59</a>]. (See  <a class="medical medical_review" href="/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a> and  <a class="medical medical_review" href="/d/html/5960.html" rel="external">"Seasonal influenza in children: Prevention with vaccines", section on 'Target groups'</a>.)</p><p></p><p class="bulletIndent2">For individuals who have contraindications to influenza vaccine, we consider on a case-by-case basis preexposure chemoprophylaxis with <a class="drug drug_general" data-topicid="9460" href="/d/drug information/9460.html" rel="external">oseltamivir</a>, for as long as influenza is present within the local community. (See  <a class="medical medical_review" href="/d/html/7017.html" rel="external">"Seasonal influenza in adults: Role of antiviral prophylaxis for prevention"</a> and  <a class="medical medical_review" href="/d/html/132409.html" rel="external">"Seasonal influenza in children: Prevention with antiviral drugs"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pneumococcal vaccine</strong> – All patients with CF should be vaccinated against pneumococcal disease, using the recommendations from the United States Centers for Disease Control and Prevention [<a href="#rid60">60</a>]. This includes the standard pneumococcal conjugate vaccine series (either the <a class="drug drug_general" data-topicid="132100" href="/d/drug information/132100.html" rel="external">15-valent pneumococcal conjugate vaccine</a> [PCV15] or <a class="drug drug_general" data-topicid="131831" href="/d/drug information/131831.html" rel="external">20-valent pneumococcal conjugate vaccine</a> [PCV20]), ideally delivered in the first 15 months of life. Children with CF and other chronic respiratory illnesses are considered at high risk of invasive pneumococcal disease and may require additional pneumococcal vaccination if their primary series did not include at least one dose of PCV20. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/6053.html" rel="external">"Pneumococcal vaccination in children", section on 'Immunization of high-risk children and adolescents'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Coronavirus disease 2019 (COVID-19) vaccine</strong> – All patients with CF should be vaccinated against COVID-19 (caused by the SARS-CoV-2 virus) as soon as they are eligible, consistent with recommendations from the CFF and the Centers for Disease Control and Prevention [<a href="#rid61">61-63</a>]. (See  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory syncytial virus (RSV) prophylaxis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nirsevimab</strong> – Immunoprophylaxis with <a class="drug drug_general" data-topicid="141488" href="/d/drug information/141488.html" rel="external">nirsevimab</a> is recommended during the first RSV season for all infants with CF, similar to other infants. For those with severe lung disease or growth failure, immunoprophylaxis is also recommended during the second RSV season [<a href="#rid64">64,65</a>]. (See  <a class="medical medical_review" href="/d/html/15389.html" rel="external">"Respiratory syncytial virus infection: Prevention in infants and children", section on 'Immunoprophylaxis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Palivizumab</strong> – We do not suggest routine prophylaxis with <a class="drug drug_general" data-topicid="9849" href="/d/drug information/9849.html" rel="external">palivizumab</a> except for infants without access to <a class="drug drug_general" data-topicid="141488" href="/d/drug information/141488.html" rel="external">nirsevimab</a> or young children with other indications. Palivizumab is a humanized monoclonal antibody against RSV that can be used to help prevent serious RSV infection in young children who are at high risk for RSV disease. A systematic review and two subsequent clinical studies have reached conflicting conclusions about the efficacy of palivizumab for young children with CF [<a href="#rid66">66-68</a>]. A retrospective CFF registry study of 4267 patients with CF reported that patients who received palivizumab during the first two years of life had similar FEV<sub>1</sub> at age seven years compared with a propensity-matched control group [<a href="#rid69">69</a>]. No differences were found in rate of hospitalization or time to first <em>Pseudomonas aeruginosa</em>-positive culture. (See  <a class="medical medical_review" href="/d/html/15389.html" rel="external">"Respiratory syncytial virus infection: Prevention in infants and children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection-control measures</strong> – There is convincing evidence that a variety of respiratory pathogens can be transmitted among individuals with CF both within and outside of the health care system. To minimize risk of transmission, the CFF has published guidelines for infection prevention and control to be applied to all individuals with CF, regardless of respiratory tract culture results [<a href="#rid70">70</a>]. Relevant to health care facilities, these include contact precautions, physical separation of patients, use of masks by patients in health care settings, and close attention to hand hygiene by patients and household contacts. (See  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Infection prevention and control'</a>.)</p><p></p><p class="headingAnchor" id="H1720241617"><span class="h2">Bronchodilators</span><span class="headingEndMark"> — </span>Airflow obstruction is a central feature of CF lung disease and is caused by several mechanisms, including bronchial plugging by purulent secretions, bronchial wall thickening due to inflammation, and airway destruction. Many patients with CF demonstrate some signs of bronchial hyperreactivity, indicated by acute improvement in FEV<sub>1</sub> following the administration of beta-adrenergic agonists, anticholinergic drugs, and/or <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a>; the greatest response is seen in those who have milder overall lung disease [<a href="#rid71">71</a>]. Most of these patients do not have findings typical of atopy (eg, no family history of asthma, elevated serum immunoglobulin E [IgE], or blood eosinophilia), in contrast with individuals with asthma but without CF [<a href="#rid72">72</a>]. A smaller subgroup has typical symptoms of asthma, such as chest tightness, wheezing and cough following exercise, or exposure to allergens or cold air [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/d/html/6369.html" rel="external">"Cystic fibrosis: Clinical manifestations of pulmonary disease", section on 'Airway reactivity'</a>.)</p><p>Bronchial hyperreactivity is also a characteristic of the small subgroup of patients with allergic bronchopulmonary aspergillosis (ABPA) [<a href="#rid73">73,74</a>]. (See <a class="local">'Allergic bronchopulmonary aspergillosis'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled beta-2 adrenergic receptor agonists</strong> – We suggest prescribing short-acting beta-2 adrenergic receptor agonists for the following situations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CF guidelines suggest short-acting bronchodilator medication immediately prior to chest physiotherapy and exercise to facilitate clearance of airway secretions, although the evidence to support this suggestion is scant. (See <a class="local">'Chest physiotherapy'</a> above and <a class="local">'Exercise'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immediately prior to inhalation of nebulized hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a>, or antibiotics for those patients who develop nonspecific bronchial constriction from these medications to minimize symptoms and potentially improve penetration and distribution of the drugs within the airways. (See <a class="local">'Inhaled airway clearance agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>As rescue medication for CF patients with evidence of airway hyperreactivity, manifested either by improvement in pulmonary function (eg, increase in FEV<sub>1</sub>) or by the patient reporting symptomatic improvement with acute use. Evidence for the efficacy of beta agonist therapy in this setting is limited to observational studies and several small randomized and nonrandomized controlled trials [<a href="#rid75">75-77</a>]. These data suggest that beta agonist therapy provides short-term improvements in pulmonary function and symptom relief in patients with clinical evidence of airway hyperresponsiveness. In addition, indirect evidence is provided by the extensive experience using beta agonists in other conditions associated with airway hyperreactivity (ie, asthma). (See  <a class="medical medical_review" href="/d/html/558.html" rel="external">"Beta agonists in asthma: Acute administration and prophylactic use"</a>.)</p><p></p><p class="bulletIndent1">Other than these indications, there is insufficient evidence to determine if chronic use of short- or long-acting beta agonists benefits lung function, frequency of exacerbations, or other outcomes, as reported by a CFF guidelines committee [<a href="#rid78">78</a>]. The published studies addressing their use are few and not uniformly supportive, although short-term benefit has been reported [<a href="#rid75">75-77,79</a>]. This assessment is consistent with the conclusions of systematic reviews [<a href="#rid80">80,81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agents without clear benefit</strong> – The anticholinergic agent <a class="drug drug_general" data-topicid="8570" href="/d/drug information/8570.html" rel="external">ipratropium</a> bromide can induce bronchodilation following acute administration in patients with CF [<a href="#rid71">71</a>]. However, a meta-analysis that included three clinical trials of <a class="drug drug_general" data-topicid="10300" href="/d/drug information/10300.html" rel="external">tiotropium</a>, a long-acting anticholinergic agent, did not show statistically significant improvement in pulmonary function tests during 12 weeks of treatment [<a href="#rid80">80,82,83</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">Theophylline</a> is infrequently prescribed in CF due both to the lack of proven efficacy and to its narrow therapeutic index and propensity to cause adverse gastrointestinal symptoms, tachycardia, and, rarely, seizures.</p><p></p><p class="headingAnchor" id="H616339875"><span class="h2">Antiinflammatory therapy</span><span class="headingEndMark"> — </span>Intense neutrophilic inflammation is a dominant pathologic feature of the airways of patients with CF. Although the inflammatory response was formerly viewed as being necessary to prevent the spread of infection, increasing information indicates that the amount of inflammation developed is probably excessive and harmful [<a href="#rid84">84,85</a>].</p><p class="headingAnchor" id="H3364619480"><span class="h3">Azithromycin</span><span class="headingEndMark"> — </span>The benefits from chronic <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> therapy for CF have been ascribed to an antiinflammatory effect.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – We suggest chronic treatment with <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> for patients six years and older who are chronically infected with <em>P. aeruginosa</em>, consistent with guidelines from the CFF published in 2013 [<a href="#rid78">78</a>]. Based on a study published since the CFF guidelines were written [<a href="#rid86">86</a>], we also suggest initiating azithromycin at the time of a first positive culture for <em>P. aeruginosa</em> for children as young as six months and continuing for at least 18 months, which was the duration of the study. Thereafter, it would be reasonable to continue treatment for those with persistent <em>P. aeruginosa</em> infection, an approach extrapolated from studies in older patients.</p><p></p><p class="bulletIndent1">For patients who are not infected with <em>P. aeruginosa</em>, we do not routinely prescribe <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, although we may do so for those who are experiencing frequent pulmonary exacerbations despite use of all other recommended therapies. Similarly, we generally stop chronic azithromycin in those patients who previously cultured <em>P. aeruginosa</em> but have had multiple negative cultures for at least one year and are having rare, if any, pulmonary exacerbations. Although the CFF guidelines published in 2013 made a weak recommendation to treat patients (≥6 years) who are culture negative for <em>P. aeruginosa</em>, they noted that the certainty and estimated net benefit were low [<a href="#rid78">78</a>]. Subsequent studies are even less supportive, as discussed below [<a href="#rid87">87,88</a>].</p><p></p><p class="bulletIndent1">Of note, concern has been raised that chronic use of oral <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> may reduce the efficacy of <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a> by having a direct effect on the bacteria, making them more resistant to aminoglycosides, as discussed below.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – We usually prescribe <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> three times a week, using approximately 10 mg/kg (up to a maximum of 500 mg per dose) for children and 500 mg for adults [<a href="#rid86">86</a>]. A study in adults shows that 250 mg/day is similarly efficacious, so daily dosing could be used for those patients who find it easier to adhere to a daily treatment schedule [<a href="#rid89">89</a>]. For the small number of patients who develop gastrointestinal side effects on a full dose, a lower dose may be used (eg, 250 mg three times a week for adult-sized patients); this dose reduction was employed in one study and was thought to be of benefit [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions and potential adverse effects</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Use in patients with nontuberculous mycobacteria</strong> – Prior to initiating treatment with <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, those patients who can expectorate a sputum sample should have a specimen examined for nontuberculous mycobacteria; macrolide therapy should <strong>not</strong> be initiated if nontuberculous mycobacteria are present. This is because macrolides are an important component of treatment regimens for <em>Mycobacterium avium</em> complex infection and should be used only as part of a multidrug regimen to avoid development of macrolide-resistant mycobacterial species. If smear-negative patients are subsequently positive by culture, the macrolide should be stopped to avoid induction of macrolide resistance. Fortunately, a single-center retrospective study reported that initial isolates of <em>M</em>. <em>avium</em> complex in CF patients receiving chronic azithromycin therapy are unlikely to be macrolide resistant [<a href="#rid91">91</a>]. The decision to treat nontuberculous mycobacteria with multiple antibiotics should be based on an assessment of the likelihood that the mycobacteria are causing tissue injury and clinical deterioration; this is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/5341.html" rel="external">"Treatment of <i>Mycobacterium avium </i>complex pulmonary infection in adults"</a>.)</p><p></p><p class="bulletIndent2">In patients <strong>without</strong> nontuberculous mycobacteria, chronic use of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> may help to prevent its acquisition; data from the CFF patient registry showed that the incidence of positive cultures for nontuberculous mycobacteria in CF patients receiving chronic azithromycin therapy was less than that of the control population [<a href="#rid92">92</a>]. A second study from this registry confirmed this finding and reported that chronic azithromycin use was associated with lower risk for new methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) infection and <em>Burkholderia cepacia</em> complex, compared with nonusers matched by propensity score [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Possible reduction in </strong><strong>tobramycin</strong><strong> efficacy</strong> – Of note, concern has been raised that chronic use of oral <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> may reduce the efficacy of inhaled or intravenous (IV) <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a>. The evidence on this issue is somewhat conflicting:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Evidence from cell culture – In vitro studies showed that <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> induced the expression of <em>Pseudomonas</em> efflux pumps that can reduce intracellular concentration of <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a> [<a href="#rid94">94</a>]. Addition of azithromycin to cultures of <em>P. aeruginosa</em> isolated from CF patients showed a reduced bactericidal effect of high concentrations of tobramycin as are achieved from inhalation in one study [<a href="#rid94">94</a>] but not another [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Inhaled <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a> – A preponderance of clinical evidence suggests that <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> probably does not prevent the beneficial effects of inhaled tobramycin. In particular, a high-quality randomized placebo-controlled trial found no significant impact of azithromycin on the effect of inhaled tobramycin on FEV<sub>1</sub> [<a href="#rid96">96</a>]. In the trial, 115 CF patients &gt;12 years of age were randomized to receive six weeks of oral azithromycin or placebo, with both groups receiving a four-week course of inhaled tobramycin for the last four weeks of the trial. The relative change in FEV<sub>1</sub> (L) from baseline, the primary endpoint of the trial, did not differ significantly for azithromycin compared with placebo (1.69 versus -1.95 percent, respectively). However, the bacterial density of <em>P</em>. <em>aeruginosa</em> in expectorated sputum increased in the azithromycin group by 0.3 log and decreased by 0.5 log in the placebo group (p&lt;0.043); the clinical significance of this is uncertain. These findings contrast with previous retrospective studies, which suggested that chronic treatment with oral azithromycin may reduce the efficacy of inhaled tobramycin but not of inhaled <a class="drug drug_general" data-topicid="9047" href="/d/drug information/9047.html" rel="external">aztreonam</a> [<a href="#rid88">88,94,97</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>IV <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a> – An antagonistic effect of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> on IV tobramycin was suggested by results from a retrospective single-center study of 173 adults on chronic azithromycin being treated for 427 episodes of pulmonary exacerbation [<a href="#rid98">98</a>]. Those on chronic azithromycin had less improvement in FEV<sub>1</sub> if they were treated with IV tobramycin compared with IV colistimethate. A larger registry-based study of 2294 patients aged 6 to 21 years being treated with tobramycin for 5022 pulmonary exacerbations found similar results [<a href="#rid99">99</a>]. The recovery of percent predicted FEV<sub>1</sub> from baseline was 21 percent lower for those receiving chronic azithromycin compared with those not taking it. Using the same registry sources, azithromycin did not reduce the recovery of FEV<sub>1</sub> if the patients were receiving IV colistimethate rather than tobramycin.</p><p></p><p class="bulletIndent2">There is no consensus among CF experts on how to respond to this provocative but as yet inconclusive information [<a href="#rid100">100</a>]. The high-quality study described above provides some assurance that <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> has minimal clinically important adverse effects on the benefits of inhaled <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a> [<a href="#rid96">96</a>]. There are no prospective randomized studies to assess the effect of azithromycin on the efficacy of IV tobramycin in the treatment of pulmonary exacerbations. In the absence of definitive information, options include avoiding chronic azithromycin for patients who are likely to be prescribed IV tobramycin in the near future, prescribing azithromycin but selecting antibiotics other than tobramycin to treat acute exacerbations in patients infected with <em>P. aeruginosa</em>, or continuing the current practice of prescribing both azithromycin and IV tobramycin while waiting for more definitive data.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prolongation of corrected QT interval (QTc)</strong> – Macrolide antibiotics can cause QTc prolongation and are associated with an excess risk of cardiac events (see  <a class="medical medical_review" href="/d/html/474.html" rel="external">"Azithromycin and clarithromycin"</a>). However, two studies failed to detect a significant risk for people with CF. In particular, a retrospective study of 68 patients with CF on chronic <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> found that their QTc interval was not significantly different from 21 control patients with CF. The authors of this study concluded that screening with an electrocardiogram prior to initiating chronic azithromycin to detect those with prolonged baseline QTc intervals would likely be sufficient to avoid complications. A secondary analysis of data from a placebo-controlled trial of azithromycin in 221 children reported that the frequency of QTc prolongation in those receiving azithromycin for a median of 18 months was no greater than those in the placebo group, with none developing a QTc longer than 500 msec [<a href="#rid86">86,101</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Evidence supporting the use of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> in patients chronically infected with <em>P. aeruginosa</em> includes the early clinical trials, which primarily enrolled this group of patients. These studies found that azithromycin improved FEV<sub>1</sub> and reduced pulmonary exacerbations [<a href="#rid89">89,90</a>]. The largest such study enrolled 168 participants who were all positive for <em>P</em>. <em>aeruginosa</em> and reported that 24 weeks of azithromycin caused a 0.094 liter improvement of FEV<sub>1</sub> relative to that of the placebo group [<a href="#rid90">90</a>]. The risk of a pulmonary exacerbation was significantly less in the azithromycin group than in the placebo group (hazard ratio 0.65). Subgroup analysis revealed that the reduction in pulmonary exacerbations occurred regardless of the response in FEV<sub>1</sub> [<a href="#rid102">102</a>]. Subsequent clinical trials have confirmed the reduction in pulmonary exacerbations in patients chronically infected with <em>P</em>. <em>aeruginosa</em> [<a href="#rid103">103</a>]. In addition, a registry-based study evaluated the effects of initiating azithromycin on pulmonary function over the subsequent three years and reported that those chronically infected with <em>P</em>. <em>aeruginosa</em> experienced 40 percent less decline in FEV<sub>1</sub> percent predicted compared with matched controls [<a href="#rid88">88</a>]. This study further supports the 2013 CFF guideline that recommends the use of azithromycin in individuals with persistent <em>P</em>. <em>aeruginosa</em> infection [<a href="#rid78">78</a>]. A retrospective study of more than 2000 patients between the ages 7 and 40 years followed for 10 years noted a reduction in rate of FEV<sub>1</sub> decline and in the frequency of pulmonary exacerbations in those receiving chronic azithromycin therapy [<a href="#rid104">104</a>]. The efficacy of azithromycin in younger patients with early <em>P</em>. <em>aeruginosa</em> infection is supported by a subsequent clinical trial in children 6 months to 18 years of age, in which azithromycin was initiated after the first positive culture and reduced the risk of pulmonary exacerbations during the subsequent 18 months (hazard ratio 0.56); this trial did not assess outcomes after 18 months of therapy [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1">The value of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> in patients uninfected with <em>P</em>. <em>aeruginosa</em> is less clear. The largest study supporting its use enrolled 260 participants randomized to azithromycin or placebo for 24 weeks [<a href="#rid105">105</a>]. There was no difference between groups in FEV<sub>1</sub>, but the azithromycin group had a 50 percent reduction in protocol-defined pulmonary exacerbations compared with placebo. However, there was no significant difference in hospitalizations or use of IV antibiotics, suggesting that the exacerbations prevented by azithromycin were relatively mild. Of note, during the open-label extension of this study, the participants who had been randomized to the placebo group showed no reduction in pulmonary exacerbations during the subsequent 24 weeks that followed their initiation of azithromycin [<a href="#rid87">87</a>]. Finally, the same registry-based study mentioned above reported no difference in FEV<sub>1</sub> decline or IV antibiotic use in the three years following initiation of azithromycin in those uninfected with <em>P</em>. <em>aeruginosa</em> [<a href="#rid83">83</a>]. For these reasons, we no longer routinely prescribe chronic azithromycin therapy for those uninfected with <em>P</em>. <em>aeruginosa</em> but may do so for patients experiencing multiple pulmonary exacerbations if other interventions have not been successful.</p><p></p><p class="bulletIndent1">Clinical trials of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> have also been performed in younger patients. A randomized trial supports extending the use of azithromycin to patients as young as six months of age following their first positive culture for <em>P. aeruginosa</em>. The trial<em> </em>enrolled 221 patients from 6 months to 18 years of age (approximately one-half were &lt;6 years old) with newly acquired <em>P. aeruginosa </em>[<a href="#rid86">86</a>]. Patients were randomized to treatment with azithromycin or placebo (in addition to a standard <em>P. aeruginosa</em> eradication regimen of inhaled <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a>) and were followed for a median of 11.8 months. Fewer patients in the azithromycin group experienced pulmonary exacerbations compared with placebo (39 versus 52 percent; hazard ratio 0.56, 95% CI 0.37-0.83). The observed treatment effect was generally consistent across different age groups, with the largest effect seen among the youngest children (ages six months to three years). Rates of <em>P. aeruginosa</em> recurrence were similar in both groups. Azithromycin was well tolerated, with no significant difference in safety endpoints between the azithromycin and placebo groups. A subsequent trial randomized 130 infants three to six months of age to received azithromycin or placebo for 36 months [<a href="#rid106">106</a>]. No statistically significant differences were seen for the prevalence of bronchiectasis detected by computed tomography (CT) and the percentage of lung volume containing diseased airways, which were the primary outcomes. However, secondary outcome analysis showed that participants who received azithromycin had 6.3 fewer days in hospital for pulmonary exacerbations (95% CI 2.1-10.5 days, p = 0.004) and 6.7 fewer days of IV antibiotics (95% CI 1.2-12.2, p = 0.018). There were inconsistent changes in sputum inflammatory markers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – The mechanisms by which macrolides improve CF lung disease are uncertain and may involve direct effects on infecting bacteria and/or suppression of the excessive inflammatory response seen in the CF lung. Macrolides are unable to kill <em>Pseudomonas</em> bacteria that are grown under conditions routinely used in clinical microbiology laboratories. However, macrolides have microbicidal activity against <em>Pseudomonas</em> bacteria that are grown under conditions that induce biofilm formation [<a href="#rid107">107</a>]. Furthermore, macrolides can block quorum sensing and reduce the ability of <em>Pseudomonas</em> to produce biofilms, which is considered one of the mechanisms by which the bacteria avoid being killed by traditional antipseudomonal antibiotics [<a href="#rid108">108</a>]. Independent of their effect on bacteria, there is mounting evidence that macrolides may be beneficial in CF lung disease by suppressing the excessive inflammatory response [<a href="#rid109">109,110</a>].</p><p></p><p class="headingAnchor" id="H3886198942"><span class="h3">Ibuprofen</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> has a limited role as an agent to reduce airway inflammation. The CFF suggests the use of high-dose ibuprofen (eg, 25 to 30 mg/kg) in children 6 through 17 years of age who have good lung function (FEV<sub>1</sub> &gt;60 percent predicted) [<a href="#rid13">13,78</a>]. This recommendation is supported by a Cochrane review [<a href="#rid111">111</a>]. Ibuprofen is not recommended for patients with more severe lung function abnormalities or those who are older than 18 years of age, because evidence is lacking to demonstrate a benefit in older patients. If high-dose ibuprofen is prescribed, pharmacokinetic studies should be performed periodically to ensure correct dosing to maintain a serum concentration of 50 to 100 mg/mL and patients should be monitored closely for the development of adverse effects [<a href="#rid112">112</a>]. (See  <a class="medical medical_review" href="/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects"</a>.)</p><p>In practice, high-dose <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> is being prescribed for only a small minority of pediatric-aged patients in the United States [<a href="#rid3">3</a>]. The requirement for periodic pharmacokinetic adjustment of the dose and concern for side effects appear to be restricting its acceptance.</p><p>The benefits of <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> are probably modest, as indicated by two long-term studies in patients with mild CF lung disease:</p><p class="bulletIndent1"><span class="glyph">●</span>A randomized trial of high-dose <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> was conducted in 85 individuals 5 to 39 years old with mild disease. Repeated pharmacokinetic studies were performed on study participants to ensure that high peak blood levels of ibuprofen (50 to 100 mcg/mL) were obtained [<a href="#rid113">113</a>]. After four years, patients in the ibuprofen group who completed the study lost only 1.5 percent of their predicted FEV<sub>1</sub> per year, compared with a loss of 3.6 percent of predicted FEV<sub>1</sub> per year for the control group. However, the beneficial effects of ibuprofen were seen only in the subgroup of patients who were younger than 13 years of age at the start of the study. Gastrointestinal bleeding and renal impairment, known adverse effects of ibuprofen, were not observed in either group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter randomized trial, a similar protocol was tested in 142 patients 6 to 18 years old [<a href="#rid114">114</a>]. The primary outcome of this study, rate of decline in FEV<sub>1</sub> percent predicted, was not statistically reduced by <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> as compared with placebo. However, the study did not meet its recruitment targets, causing it to be underpowered to detect a difference of 2 percent. The group treated with ibuprofen did show a statistically significant reduction in the rate of decline of FVC percent predicted (0.07±0.51 versus -1.62±0.52), which was a secondary endpoint of the study.</p><p></p><p class="headingAnchor" id="H4134335182"><span class="h3">Inhaled glucocorticoids</span><span class="headingEndMark"> — </span>Inhaled glucocorticoids are appropriate for CF patients who have definite signs and symptoms of asthma, including patients with asthmatic symptoms in the setting of ABPA. They are not routinely recommended for patients without these indications [<a href="#rid14">14,78</a>]. This is because there is insufficient evidence for benefit [<a href="#rid115">115</a>]; some trials suggest modest benefit and others report no effect [<a href="#rid116">116-119</a>]. One of the reasons for caution is that inhaled glucocorticoids may modestly impair linear growth in children with CF or asthma [<a href="#rid120">120,121</a>]. These effects are dose related and less severe than those seen in children treated with systemic glucocorticoids. (See  <a class="medical medical_review" href="/d/html/540.html" rel="external">"Major side effects of inhaled glucocorticoids", section on 'Growth deceleration'</a>.)</p><p class="headingAnchor" id="H3189248271"><span class="h3">Other medications</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Short-term use of systemic glucocorticoids</strong> – Some CF clinicians administer a brief course of corticosteroids to selected patients during an acute exacerbation, although the evidence is limited and there is considerable variation in practice. The rationale and our approach are described separately. (See  <a class="medical medical_review" href="/d/html/110933.html" rel="external">"Cystic fibrosis: Management of pulmonary exacerbations", section on 'Glucocorticoids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agents not recommended</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic use of systemic glucocorticoids</strong> – We agree with the guidelines committee of the CFF, which recommends against the routine chronic use of oral corticosteroids for children with CF aged 6 to 18 years, in the absence of asthma or ABPA, because of the associated adverse effects [<a href="#rid14">14,78</a>]. Although a small randomized trial suggested that chronic treatment was associated with modest improvements in pulmonary function [<a href="#rid122">122</a>], a long-term follow-up study documented important adverse effects, including abnormal glucose metabolism, cataracts, and growth failure [<a href="#rid123">123</a>]. We also do not recommend their use in adults, because of the same adverse effects (other than growth failure).</p><p></p><p class="bulletIndent2">By contrast, patients with acute ABPA typically require a prolonged course of systemic glucocorticoids, in conjunction with other medical therapy. (See  <a class="medical medical_review" href="/d/html/104431.html" rel="external">"Treatment of allergic bronchopulmonary aspergillosis", section on 'Acute ABPA'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cromolyn</strong> – Sodium <a class="drug drug_general" data-topicid="9300" href="/d/drug information/9300.html" rel="external">cromolyn</a> (cromoglycate) and <a class="drug drug_general" data-topicid="9987" href="/d/drug information/9987.html" rel="external">nedocromil</a> are antiinflammatory drugs that have been used for the treatment of asthma; nedocromil is no longer available in the United States. Neither has been studied adequately in patients with CF. The few small studies that have been performed detected no benefit or adverse effects. As an example, one double-blind, placebo-controlled, crossover study was performed on 14 patients with CF and bronchial hyperreactivity; no improvement in clinical status or pulmonary function tests was seen among patients receiving sodium cromoglycate [<a href="#rid124">124</a>].</p><p></p><p class="bulletIndent2">Given the lack of adequate studies of <a class="drug drug_general" data-topicid="9300" href="/d/drug information/9300.html" rel="external">cromolyn</a> in patients with CF, the relatively high expense, and the evidence of inferiority relative to inhaled glucocorticoids in patients with asthma [<a href="#rid125">125</a>], we do not prescribe cromoglycate or <a class="drug drug_general" data-topicid="9987" href="/d/drug information/9987.html" rel="external">nedocromil</a> for our patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Free sulfhydryl agents</strong> – Because oxidant stress has been hypothesized to be a mechanism of tissue injury in CF, interventions that bolster antioxidant defenses have been promoted for CF treatment. The glutathione peroxidase system, which can limit oxidant injury, requires a source of free sulfhydryl compounds to function and has led to the unapproved use of glutathione and <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a>. These compounds can also cleave disulfide bonds within mucus glycoproteins and can liquefy CF sputum in vitro.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Inhaled and oral </strong><a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a> – We do not suggest use of inhaled N-acetylcysteine, consistent with guidance from the CFF [<a href="#rid78">78</a>]. Although originally developed as an inhaled mucolytic agent, there are no well-designed studies demonstrating its clinical utility [<a href="#rid13">13,126</a>]. Furthermore, its potential to induce airway inflammation and/or bronchospasm in a subgroup of patients and to inhibit ciliary function has led to reduction in its use. These deficiencies, in conjunction with its disagreeable odor and time required for administration, cause us not to prescribe it. A randomized placebo-controlled trial of oral N-acetylcysteine reported no improvement in FEV<sub>1</sub> from baseline following 24 weeks of treatment [<a href="#rid127">127</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Inhaled and oral glutathione</strong> – Despite some encouraging results from anecdotal reports and case series, controlled clinical trials have not found significant clinical benefit from oral or inhaled glutathione [<a href="#rid128">128,129</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Docosahexaenoic acid (DHA)</strong> – Oral supplementation with omega-3 fatty acids has been proposed as treatment for CF due to their antiinflammatory properties and because people with CF have been found to have decreased levels [<a href="#rid130">130</a>] (see  <a class="medical medical_review" href="/d/html/5365.html" rel="external">"Fish oil: Physiologic effects and administration"</a>). However, a randomized placebo-controlled trial that enrolled 96 patients with CF with a mean age of 14.6 years found no benefit from 48 weeks of treatment in FEV<sub>1</sub>, pulmonary exacerbations, or quality of life [<a href="#rid131">131</a>].</p><p></p><p class="headingAnchor" id="H360635096"><span class="h1">CHRONIC ANTIBIOTIC TREATMENT</span><span class="headingEndMark"> — </span>The course of pulmonary disease in CF is characterized by chronic infections with multiple organisms, causing a gradual decline in pulmonary function with periodic acute exacerbations heralded by symptoms such as increased cough, sputum production, and shortness of breath.</p><p>Chronic infection with <em>P. aeruginosa</em> is an independent risk factor for accelerated loss of pulmonary function and decreased survival [<a href="#rid132">132,133</a>]. The prevalence of <em>P. aeruginosa </em>increases with age; it can be isolated in approximately 25 percent of infants with CF and up to 75 percent of adults  (<a class="graphic graphic_figure graphicRef74073" href="/d/graphic/74073.html" rel="external">figure 2</a>). Of note, continuous treatment with oral antibiotics (other than <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>) and elective periodic hospitalization for pulmonary toilet ("clean-out") are not recommended [<a href="#rid78">78,134-136</a>]. Treatment of chronic airway infection with antibiotics is discussed separately. (See  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection"</a>.)</p><p class="headingAnchor" id="H1725408599"><span class="h1">TREATMENT OF ACUTE EXACERBATIONS</span><span class="headingEndMark"> — </span>The clinical course of CF is frequently complicated by acute pulmonary exacerbations, superimposed on a gradual decline in pulmonary function. Treatment of exacerbations with systemic antibiotics is a mainstay of CF care and is recommended in virtually all consensus guidelines. Management of acute exacerbations, including selection of antibiotics, is discussed separately. (See  <a class="medical medical_review" href="/d/html/110933.html" rel="external">"Cystic fibrosis: Management of pulmonary exacerbations"</a> and  <a class="medical medical_review" href="/d/html/140721.html" rel="external">"Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations"</a>.)</p><p class="headingAnchor" id="H507640875"><span class="h1">OTHER PULMONARY COMPLICATIONS</span><span class="headingEndMark"> — </span>Spontaneous pneumothorax and hemoptysis are well-recognized complications of CF, particularly among adults. These complications have become increasingly common as overall survival continues to improve [<a href="#rid137">137,138</a>].</p><p class="headingAnchor" id="H381373066"><span class="h2">Spontaneous pneumothorax</span><span class="headingEndMark"> — </span>Spontaneous pneumothorax occurs in 3 to 4 percent of patients with CF during their lifetime [<a href="#rid139">139</a>]. Major risk factors are older age and more severe obstructive lung disease. Recurrent pneumothorax is an indication for referral to a transplantation center [<a href="#rid72">72,140</a>]. Treatment of pneumothorax in CF patients does not differ from that of patients with other types of lung disease. (See  <a class="medical medical_review" href="/d/html/6691.html" rel="external">"Treatment of secondary spontaneous pneumothorax in adults"</a> and  <a class="medical medical_review" href="/d/html/6340.html" rel="external">"Spontaneous pneumothorax in children"</a>.)</p><p>Guidelines have been published for the management of pneumothorax in patients with CF [<a href="#rid141">141</a>]. Pleurodesis, when needed to address persistent air leaks or other pleural space problems, should not preclude subsequent lung transplantation [<a href="#rid142">142,143</a>]; however, it is associated with greater operative blood loss and renal dysfunction [<a href="#rid144">144</a>]. Avoidance of more aggressive pleural stripping procedures or the use of talc may be advisable to reduce subsequent bleeding complications if and when the native lungs are removed at transplantation [<a href="#rid145">145</a>]. Collaboration between the consulting CF center surgeon and a lung transplant surgeon is recommended.</p><p class="headingAnchor" id="H2223011929"><span class="h2">Hemoptysis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scant hemoptysis</strong> – Blood streaking in sputum is a common occurrence in patients with CF and is often accompanied by other signs of a pulmonary exacerbation (see  <a class="medical medical_review" href="/d/html/110933.html" rel="external">"Cystic fibrosis: Management of pulmonary exacerbations"</a>). This requires no special treatment beyond the usual approach for the exacerbation, plus assuring that vitamin K deficiency is not a contributing factor and stopping nonsteroidal antiinflammatory drugs (NSAIDs) that may inhibit coagulation  (<a class="graphic graphic_table graphicRef97388" href="/d/graphic/97388.html" rel="external">table 3</a>), as outlined in a 2010 guideline [<a href="#rid141">141</a>]. Because even minor hemoptysis can be alarming to patients, reassurance as to its usually benign nature is needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild or moderate hemoptysis</strong> – Patients with mild or moderate hemoptysis (ie, those who expectorate approximately 5 to 240 mL of blood in 24 hours) should be considered for hospital admission based on the volume of blood expectorated, ability to clear the airways, degree of shortness of breath, and adequacy of ventilation and oxygenation. In addition to supportive care  (<a class="graphic graphic_table graphicRef97388" href="/d/graphic/97388.html" rel="external">table 3</a>), treatment for a pulmonary exacerbation should be initiated because it is likely that the bleeding is caused by infection and inflammation that has compromised airway integrity and eroded into an underlying blood vessel that is part of the bronchial arterial circulation. (See  <a class="medical medical_review" href="/d/html/110933.html" rel="external">"Cystic fibrosis: Management of pulmonary exacerbations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Massive hemoptysis</strong> – Massive hemoptysis is defined in the CF population as acute bleeding of more than 240 mL within 24 hours or recurrent bleeding of more than 100 mL daily for several days [<a href="#rid141">141</a>]. It is more common in patients with advanced lung disease (approximately 2 percent of these patients per year), but can also occur in other patients who have regions of the lung with advanced bronchiectasis [<a href="#rid138">138,146,147</a>]. Massive hemoptysis increases the risk of progression to lung transplant and death without lung transplant [<a href="#rid140">140,146</a>]. In patients with severe lung disease, massive hemoptysis is an indication for lung transplant referral [<a href="#rid140">140</a>].</p><p></p><p class="bulletIndent1">Emergency management of unstable patients with massive hemoptysis (hemodynamic instability or impending respiratory failure) is discussed separately. (See  <a class="medical medical_review" href="/d/html/4394.html" rel="external">"Evaluation and management of life-threatening hemoptysis"</a> and  <a class="medical medical_review" href="/d/html/6370.html" rel="external">"Hemoptysis in children", section on 'Control of life-threatening hemoptysis'</a>.)</p><p></p><p class="bulletIndent1">Management of massive hemoptysis in patients with CF is outlined in a 2010 guideline [<a href="#rid141">141</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bronchial artery embolization (BAE) – BAE is an important tool for managing massive hemoptysis and should be implemented promptly for all patients who are clinically unstable [<a href="#rid148">148,149</a>]. It should be strongly considered for stable patients who have limited respiratory reserve that places them at high risk for bad outcomes should there be a recurring event. The CF guidelines advise against performing bronchoscopy prior to BAE because bronchoscopy is unlikely to precisely localize the source of bleeding in bronchiectatic airways and may delay proceeding to BAE [<a href="#rid141">141</a>]. CT angiography may be beneficial if it can be performed without significantly delaying BAE because it may be able to identify the origin and course of the bronchial arteries that need to be occluded. (See  <a class="medical medical_review" href="/d/html/4394.html" rel="external">"Evaluation and management of life-threatening hemoptysis"</a> and  <a class="medical medical_review" href="/d/html/6370.html" rel="external">"Hemoptysis in children", section on 'Bronchial artery embolization'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Implement supportive measures (treating with antibiotics and bronchodilators and stopping NSAIDs), similar to mild or moderate hemoptysis  (<a class="graphic graphic_table graphicRef97388" href="/d/graphic/97388.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suspend chest physiotherapy. Noninvasive positive pressure ventilation (eg, bilevel positive airway pressure, BPAP) should generally be discontinued as long as the bleeding continues.</p><p></p><p class="bulletIndent1">Other than proceeding promptly to BAE and maximizing treatment as one would for a severe pulmonary exacerbation, the management of massive hemoptysis in CF is similar to that for patients with other causes of bronchiectasis. (See  <a class="medical medical_review" href="/d/html/6370.html" rel="external">"Hemoptysis in children", section on 'Therapeutic interventions for selected patients'</a>.)</p><p></p><p>The role of antifibrinolytic drugs in management of hemoptysis is uncertain. Evidence regarding the use of these drugs to treat hemoptysis is limited to anecdotal reports and small case series of CF patients [<a href="#rid147">147,148,150</a>] and extrapolation from studies of patients with non-CF bronchiectasis [<a href="#rid151">151,152</a>]. A 2019 report detailed the outcomes of 21 patients with CF at a single center whose treatment followed a set protocol that used <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> and/or epsilon-aminocaproic acid to treat hemoptysis [<a href="#rid150">150</a>]. The patients had cessation of bleeding in a mean of two days, including two patients with severe hemoptysis and 11 with moderate hemoptysis. More clinical trials are needed to determine if and when antifibrinolytic drugs should be used. (See  <a class="medical medical_review" href="/d/html/6370.html" rel="external">"Hemoptysis in children", section on 'Interventions to improve hemostasis'</a> and  <a class="medical medical_review" href="/d/html/4394.html" rel="external">"Evaluation and management of life-threatening hemoptysis", section on 'Correct bleeding diathesis'</a>.)</p><p class="headingAnchor" id="H1365793562"><span class="h2">Allergic bronchopulmonary aspergillosis</span><span class="headingEndMark"> — </span>Although invasive fungal disease is rare in patients with CF, allergic bronchopulmonary aspergillosis (ABPA) is increasingly recognized in CF patients. It can be difficult to distinguish between ABPA and the progressive pulmonary disease that is typical in CF because the symptoms and radiographic features are often similar.</p><p>In most CF centers, patients are screened with annual evaluation of total serum IgE; a sudden increase should prompt further investigation for possible ABPA. Patients should also be evaluated for ABPA if they have a marked exacerbation of wheezing or otherwise unexplained deterioration in lung function despite antibiotic therapy. (See  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Aspergillus species'</a> and  <a class="medical medical_review" href="/d/html/2419.html" rel="external">"Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis"</a>.)</p><p>Patients who grow <em>Aspergillus</em> species from respiratory cultures but who do not have evidence of ABPA should be observed closely but usually do not warrant treatment, except perhaps for those anticipating lung transplant. Patients with confirmed ABPA should be treated. (See  <a class="medical medical_review" href="/d/html/104431.html" rel="external">"Treatment of allergic bronchopulmonary aspergillosis"</a>.)</p><p class="headingAnchor" id="H3621093869"><span class="h2">Pulmonary hypertension</span><span class="headingEndMark"> — </span>Advanced chronic lung disease in CF can be complicated by pulmonary hypertension, which is correlated with severity of lung disease. In most cases, CF patients with pulmonary hypertension have severe pulmonary compromise (eg, forced expiratory volume in one second [FEV<sub>1</sub>] &lt;40 percent predicted, hypoxemia, or hypercapnia) and the pulmonary hypertension is often identified in the context of evaluation for lung transplantation. (See  <a class="medical medical_review" href="/d/html/6369.html" rel="external">"Cystic fibrosis: Clinical manifestations of pulmonary disease", section on 'Pulmonary hypertension'</a>.)</p><p class="headingAnchor" id="H3389286968"><span class="h1">ADVANCED LUNG DISEASE</span><span class="headingEndMark"> — </span>When CF lung disease becomes severe, additional evaluation and treatment are overlaid onto the standard therapies that are applicable to all patients with CF lung disease. Discussions regarding lung transplantation should occur well before it becomes urgent [<a href="#rid140">140</a>]. Early referral to a transplant program allows barriers to be recognized and corrected. (See  <a class="medical medical_review" href="/d/html/129117.html" rel="external">"Cystic fibrosis: Management of advanced lung disease"</a>.)</p><p class="headingAnchor" id="H2833323334"><span class="h1">PREGNANCY</span><span class="headingEndMark"> — </span>The number of pregnancies reported annually to the Cystic Fibrosis Foundation (CFF) patient registry increased from 309 in 2019 to 675 in 2021, likely due to increased fertility associated with taking <a class="drug drug_general" data-topicid="122968" href="/d/drug information/122968.html" rel="external">elexacaftor-tezacaftor-ivacaftor</a> (ETI) [<a href="#rid3">3,153</a>]. Subfertility in women with CF and the potential benefits and risks of CF transmembrane conductance regulator (CFTR) modulators during pregnancy and lactation are discussed separately. (See  <a class="medical medical_review" href="/d/html/6367.html" rel="external">"Cystic fibrosis: Clinical manifestations and diagnosis", section on 'Infertility'</a> and  <a class="medical medical_review" href="/d/html/118899.html" rel="external">"Cystic fibrosis: Treatment with CFTR modulators", section on 'Pregnancy and lactation'</a>.)</p><p>Compared with women without CF, women with CF have higher risks of serious complications during pregnancy (including preterm birth, cesarean delivery, pneumonia, requirement for mechanical ventilation, and death), but these events are rare and the absolute risk is low [<a href="#rid154">154-158</a>]. The overall mortality rate during labor and birth was 1 percent [<a href="#rid154">154</a>].</p><p>For women with mild to moderate pulmonary disease (ie, forced expiratory volume in one second [FEV<sub>1</sub>] &gt;60 percent predicted), the frequency of treatment for pulmonary exacerbations was increased during pregnancy [<a href="#rid159">159</a>]. Women with severe lung disease, especially those with pulmonary hypertension, tend to have worse outcomes [<a href="#rid160">160</a>], although successful outcomes have been reported in some case series [<a href="#rid161">161,162</a>]. In addition to the underlying pulmonary disease, comorbidities that may complicate pregnancies include CF-related diabetes, cardiac conduction disorders, acute renal failure, and thrombophilia/antiphospholipid syndrome.</p><p>Most retrospective studies have concluded that pregnancy does not affect the subsequent course of lung disease [<a href="#rid159">159,160,163-165</a>]. However, a registry-based study of 296 people with CF who became parents during 2016 to 2019 (women by pregnancy or men whose partners were pregnant) reported that, during the year following delivery, there were small but significant reductions in FEV<sub>1</sub> and body mass index as well as a 30 percent increase in days of intravenous (IV) antibiotic treatment for pulmonary exacerbations [<a href="#rid166">166</a>]. Subgroup analysis showed that those on CFTR modulator therapy did not experience the drop in FEV<sub>1</sub>, but modulators did not prevent the adverse effects on body mass index or pulmonary exacerbation treatment. The rigors of infant care leading to decreased time for self-care is a likely explanation for some of the reduction in health status.</p><p>The general principles of pregnancy management for women with CF include [<a href="#rid167">167-169</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Achieving optimal, stable pulmonary function prior to conception and carefully monitoring during pregnancy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Providing genetic counseling regarding the risk of disease in offspring, carrier testing of the father, and options for prenatal diagnosis (see  <a class="medical medical_review" href="/d/html/463.html" rel="external">"Cystic fibrosis: Carrier screening"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Close monitoring of maternal nutrition and weight gain</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening for gestational diabetes early in pregnancy because of the increased risk for secondary insulin deficiency and CF-related diabetes (see  <a class="medical medical_review" href="/d/html/14544.html" rel="external">"Cystic fibrosis-related diabetes mellitus"</a>)</p><p></p><p class="headingAnchor" id="H2653007012"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109226.html" rel="external">"Society guideline links: Cystic fibrosis"</a>.)</p><p class="headingAnchor" id="H11003755"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16906.html" rel="external">"Patient education: Cystic fibrosis (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/86714.html" rel="external">"Patient education: Bronchiectasis in children (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H36"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Medical therapies to manage cystic fibrosis (CF) lung disease are summarized in the table  (<a class="graphic graphic_table graphicRef119343" href="/d/graphic/119343.html" rel="external">table 1</a>). The following treatment recommendations apply to children six years of age and older, unless otherwise specified.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CF transmembrane conductance regulator (CFTR) modulators</strong> – All patients with CF should undergo <em>CFTR</em> genotyping to determine if they carry one of the mutations approved for CFTR modulator therapy  (<a class="graphic graphic_table graphicRef130494" href="/d/graphic/130494.html" rel="external">table 2</a>). Selection of the CFTR modulator depends on the CFTR mutation and the child's age, as outlined in the algorithms  (<a class="graphic graphic_algorithm graphicRef130531" href="/d/graphic/130531.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef130532" href="/d/graphic/130532.html" rel="external">algorithm 2</a>). (See <a class="local">'CFTR modulators'</a> above and  <a class="medical medical_review" href="/d/html/118899.html" rel="external">"Cystic fibrosis: Treatment with CFTR modulators"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Airway clearance therapies</strong> – All patients should have an airway clearance regimen with the following (see <a class="local">'Airway clearance therapies'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients ≥12 years who are on <a class="drug drug_general" data-topicid="122968" href="/d/drug information/122968.html" rel="external">elexacaftor-tezacaftor-ivacaftor</a> (ETI) and who have normal or mildly reduced lung function, we suggest <strong>not</strong> using inhaled airway clearance therapies (nebulized dornase alfa [<a class="drug drug_general" data-topicid="9385" href="/d/drug information/9385.html" rel="external">DNase</a>] and hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). This suggestion is based on a 12-week randomized trial that found no benefit of continuing inhaled airway clearance therapies in such patients.</p><p></p><p class="bulletIndent2">For most other patients, we recommend chronic use of nebulized dornase alfa (<a class="drug drug_general" data-topicid="9385" href="/d/drug information/9385.html" rel="external">DNase</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>) and suggest hypertonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). The evidence for benefit is stronger for DNase compared with hypertonic saline, and for patients who are older and/or have more severe lung disease. For children &lt;5 years, our practice is to offer treatment to those with chronic respiratory symptoms or who have more than rare pulmonary exacerbations. (See <a class="local">'Inhaled airway clearance agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All patients who produce sputum should be encouraged to adhere to a regular regimen of chest physiotherapy. In addition, all patients should be encouraged to engage in regular exercise. (See <a class="local">'Chest physiotherapy'</a> above and <a class="local">'Exercise'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with evidence of airway hyperreactivity (either based on spirometry or subjective improvement in symptoms in response to treatment) who experience intermittent episodes of acute symptomatic bronchospasm, we suggest use of an inhaled short-acting beta-adrenergic agonist as needed for symptomatic relief (ie, as a rescue medication) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Bronchodilators'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Azithromycin</strong> – We suggest initiating chronic <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> therapy at the time of the first positive culture for <em>Pseudomonas aeruginosa</em> in patients as young as ≥6 months old (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>); we continue the treatment for as long as the patient remains culture positive for <em>P. aeruginosa</em>. We do not prescribe azithromycin in the absence of chronic <em>P. aeruginosa</em> infection, unless the patient is having frequent pulmonary exacerbations unresponsive to other standard therapy. The benefits of azithromycin appear to be due to an antiinflammatory effect. There is some evidence that chronic azithromycin may reduce the efficacy of inhaled or intravenous (IV) <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a>. (See <a class="local">'Azithromycin'</a> above.)</p><p></p><p class="bulletIndent1">All patients who produce sputum should be tested for nontuberculous mycobacteria prior to initiating <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> treatment to avoid the possibility of inducing antibiotic-resistant organisms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ibuprofen</strong> – Treatment with high-dose <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> is a reasonable option in children and young adolescents with good lung function (&gt;60 percent predicted). Although this practice is suggested by the Cystic Fibrosis Foundation (CFF) guidelines, the evidence is limited and it is rarely used in clinical practice. Furthermore, there is inadequate evidence to support this suggestion for adult patients or for patients with poor lung function. (See <a class="local">'Ibuprofen'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled glucocorticoids</strong> – Inhaled glucocorticoids are appropriate for CF patients who have clear signs and symptoms of asthma, including patients with asthmatic symptoms in the setting of allergic bronchopulmonary aspergillosis (ABPA). We suggest <strong>not</strong> routinely using inhaled glucocorticoids in patients without these indications (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For this group, there are no clear benefits and the treatment may impair linear growth. For patients with CF and asthma, inhaled corticosteroids have greater clinical benefit and the treatment may be considered along with other antiasthmatic treatments. (See <a class="local">'Inhaled glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotics</strong> – CF lung disease typically has a course of intermittent acute exacerbations, superimposed on a gradual decline in pulmonary function. Exacerbations are treated with antibiotics given either orally, via inhalation, or IV, depending on the infecting organisms and the severity of the exacerbation. The role of antibiotics in the treatment of CF lung disease is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Management of pulmonary exacerbations is discussed separately. (See  <a class="medical medical_review" href="/d/html/110933.html" rel="external">"Cystic fibrosis: Management of pulmonary exacerbations"</a> and  <a class="medical medical_review" href="/d/html/140721.html" rel="external">"Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations"</a>.)</p><p></p><p class="bulletIndent1">Spontaneous pneumothorax and hemoptysis are well-recognized complications of CF, particularly among individuals with advanced lung disease. (See <a class="local">'Other pulmonary complications'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet 2021; 397:2195.</a></li><li><a class="nounderline abstract_t">Saferali A, Qiao D, Kim W, et al. CFTR variants are associated with chronic bronchitis in smokers. Eur Respir J 2022; 60.</a></li><li class="breakAll">Cystic Fibrosis Foundation. 2021 CF Foundation Patient Registry Highlights Report. Available at: https://www.cff.org/medical-professionals/patient-registry (Accessed on October 24, 2022).</li><li><a class="nounderline abstract_t">Miller AC, Comellas AP, Hornick DB, et al. Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions. Proc Natl Acad Sci U S A 2020; 117:1621.</a></li><li><a class="nounderline abstract_t">Mahadeva R, Webb K, Westerbeek RC, et al. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. BMJ 1998; 316:1771.</a></li><li><a class="nounderline abstract_t">Mérelle ME, Schouten JP, Gerritsen J, Dankert-Roelse JE. Influence of neonatal screening and centralized treatment on long-term clinical outcome and survival of CF patients. Eur Respir J 2001; 18:306.</a></li><li><a class="nounderline abstract_t">Walters S, Britton J, Hodson ME. Hospital care for adults with cystic fibrosis: an overview and comparison between special cystic fibrosis clinics and general clinics using a patient questionnaire. Thorax 1994; 49:300.</a></li><li><a class="nounderline abstract_t">Johnson C, Butler SM, Konstan MW, et al. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest 2003; 123:20.</a></li><li><a class="nounderline abstract_t">Shak S. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis. Chest 1995; 107:65S.</a></li><li><a class="nounderline abstract_t">Vasconcellos CA, Allen PG, Wohl ME, et al. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994; 263:969.</a></li><li><a class="nounderline abstract_t">Martin C, Burnet E, Ronayette-Preira A, et al. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease. Respir Med Res 2021; 80:100829.</a></li><li><a class="nounderline abstract_t">Bec R, Reynaud-Gaubert M, Arnaud F, et al. Chest computed tomography improvement in patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: Early report. Eur J Radiol 2022; 154:110421.</a></li><li><a class="nounderline abstract_t">Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957.</a></li><li><a class="nounderline abstract_t">Lahiri T, Hempstead SE, Brady C, et al. Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis. Pediatrics 2016; 137.</a></li><li><a class="nounderline abstract_t">Cystic Fibrosis Foundation, Borowitz D, Robinson KA, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009; 155:S73.</a></li><li><a class="nounderline abstract_t">Mayer-Hamblett N, Ratjen F, Russell R, et al. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Lancet Respir Med 2023; 11:329.</a></li><li><a class="nounderline abstract_t">Suri R, Metcalfe C, Lees B, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001; 358:1316.</a></li><li><a class="nounderline abstract_t">Suri R, Grieve R, Normand C, et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax 2002; 57:841.</a></li><li><a class="nounderline abstract_t">Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev 2021; 3:CD001127.</a></li><li><a class="nounderline abstract_t">Konstan MW, Wagener JS, Pasta DJ, et al. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol 2011; 46:545.</a></li><li><a class="nounderline abstract_t">Voldby C, Green K, Philipsen L, et al. Withdrawal of dornase alfa increases ventilation inhomogeneity in children with cystic fibrosis. J Cyst Fibros 2021; 20:949.</a></li><li><a class="nounderline abstract_t">Goralski JL, Wu D, Thelin WR, et al. The in vitro effect of nebulised hypertonic saline on human bronchial epithelium. Eur Respir J 2018; 51.</a></li><li><a class="nounderline abstract_t">Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354:241.</a></li><li><a class="nounderline abstract_t">Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354:229.</a></li><li><a class="nounderline abstract_t">Donaldson SH, Danielle Samulski T, LaFave C, et al. A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: Effect on mucociliary clearance and clinical outcomes. J Cyst Fibros 2020; 19:942.</a></li><li><a class="nounderline abstract_t">Ratjen F, Davis SD, Stanojevic S, et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2019; 7:802.</a></li><li><a class="nounderline abstract_t">Tiddens HAWM, Chen Y, Andrinopoulou ER, et al. The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial. Lancet Respir Med 2022; 10:669.</a></li><li><a class="nounderline abstract_t">Wark P, McDonald VM, Smith S. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2023; 6:CD001506.</a></li><li><a class="nounderline abstract_t">Stahl M, Wielpütz MO, Ricklefs I, et al. Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRESIS). A Randomized, Double-Blind, Controlled Study. Am J Respir Crit Care Med 2019; 199:1238.</a></li><li><a class="nounderline abstract_t">Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011; 38:1071.</a></li><li><a class="nounderline abstract_t">Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012; 185:645.</a></li><li><a class="nounderline abstract_t">De Boeck K, Haarman E, Hull J, et al. Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial. J Cyst Fibros 2017; 16:380.</a></li><li><a class="nounderline abstract_t">Flume PA, Amelina E, Daines CL, et al. Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study. J Cyst Fibros 2021; 20:1003.</a></li><li><a class="nounderline abstract_t">Dentice R, Elkins M. Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database Syst Rev 2021; 3:CD007923.</a></li><li><a class="nounderline abstract_t">Flume PA, Robinson KA, O'Sullivan BP, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009; 54:522.</a></li><li><a class="nounderline abstract_t">Lester MK, Flume PA. Airway-clearance therapy guidelines and implementation. Respir Care 2009; 54:733.</a></li><li><a class="nounderline abstract_t">Trimble A, Zeman K, Wu J, et al. Effect of airway clearance therapies on mucociliary clearance in adults with cystic fibrosis: A randomized controlled trial. PLoS One 2022; 17:e0268622.</a></li><li><a class="nounderline abstract_t">Warnock L, Gates A. Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis. Cochrane Database Syst Rev 2023; 4:CD001401.</a></li><li><a class="nounderline abstract_t">Arias Llorente RP, Bousoño García C, Díaz Martín JJ. Treatment compliance in children and adults with cystic fibrosis. J Cyst Fibros 2008; 7:359.</a></li><li><a class="nounderline abstract_t">Oermann CM, Swank PR, Sockrider MM. Validation of an instrument measuring patient satisfaction with chest physiotherapy techniques in cystic fibrosis. Chest 2000; 118:92.</a></li><li><a class="nounderline abstract_t">Wilson LM, Morrison L, Robinson KA. Airway clearance techniques for cystic fibrosis: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev 2019; 1:CD011231.</a></li><li><a class="nounderline abstract_t">Morrison L, Milroy S. Oscillating devices for airway clearance in people with cystic fibrosis. Cochrane Database Syst Rev 2020; 4:CD006842.</a></li><li><a class="nounderline abstract_t">Burnham P, Stanford G, Stewart R. Autogenic drainage for airway clearance in cystic fibrosis. Cochrane Database Syst Rev 2021; 12:CD009595.</a></li><li><a class="nounderline abstract_t">Main E, Rand S. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. Cochrane Database Syst Rev 2023; 5:CD002011.</a></li><li><a class="nounderline abstract_t">Wilson LM, Saldanha IJ, Robinson KA. Active cycle of breathing technique for cystic fibrosis. Cochrane Database Syst Rev 2023; 2:CD007862.</a></li><li><a class="nounderline abstract_t">McIlwaine M, Wong LT, Chilvers M, Davidson GF. Long-term comparative trial of two different physiotherapy techniques; postural drainage with percussion and autogenic drainage, in the treatment of cystic fibrosis. Pediatr Pulmonol 2010; 45:1064.</a></li><li><a class="nounderline abstract_t">McIlwaine PM, Wong LT, Peacock D, Davidson AG. Long-term comparative trial of conventional postural drainage and percussion versus positive expiratory pressure physiotherapy in the treatment of cystic fibrosis. J Pediatr 1997; 131:570.</a></li><li><a class="nounderline abstract_t">McIlwaine MP, Alarie N, Davidson GF, et al. Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosis. Thorax 2013; 68:746.</a></li><li><a class="nounderline abstract_t">Sontag MK, Quittner AL, Modi AC, et al. Lessons learned from a randomized trial of airway secretion clearance techniques in cystic fibrosis. Pediatr Pulmonol 2010; 45:291.</a></li><li><a class="nounderline abstract_t">Main E. Airway clearance research in CF: the 'perfect storm' of strong preference and effortful participation in long-term, non-blinded studies. Thorax 2013; 68:701.</a></li><li><a class="nounderline abstract_t">Radtke T, Smith S, Nevitt SJ, et al. Physical activity and exercise training in cystic fibrosis. Cochrane Database Syst Rev 2022; 8:CD002768.</a></li><li><a class="nounderline abstract_t">Schneiderman-Walker J, Pollock SL, Corey M, et al. A randomized controlled trial of a 3-year home exercise program in cystic fibrosis. J Pediatr 2000; 136:304.</a></li><li><a class="nounderline abstract_t">Rovedder PM, Flores J, Ziegler B, et al. Exercise programme in patients with cystic fibrosis: a randomized controlled trial. Respir Med 2014; 108:1134.</a></li><li><a class="nounderline abstract_t">Hebestreit H, Kriemler S, Schindler C, et al. Effects of a Partially Supervised Conditioning Program in Cystic Fibrosis: An International Multicenter, Randomized Controlled Trial (ACTIVATE-CF). Am J Respir Crit Care Med 2022; 205:330.</a></li><li><a class="nounderline abstract_t">Dwyer TJ, Daviskas E, Zainuldin R, et al. Effects of exercise and airway clearance (positive expiratory pressure) on mucus clearance in cystic fibrosis: a randomised crossover trial. Eur Respir J 2019; 53.</a></li><li><a class="nounderline abstract_t">Heinz KD, Walsh A, Southern KW, et al. Exercise versus airway clearance techniques for people with cystic fibrosis. Cochrane Database Syst Rev 2022; 6:CD013285.</a></li><li><a class="nounderline abstract_t">Viviani L, Assael BM, Kerem E, ECFS (A) H1N1 study group. Impact of the A (H1N1) pandemic influenza (season 2009-2010) on patients with cystic fibrosis. J Cyst Fibros 2011; 10:370.</a></li><li><a class="nounderline abstract_t">Jain M, Thomson AH. Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis. J R Soc Med 2009; 102 Suppl 1:23.</a></li><li><a class="nounderline abstract_t">Malfroot A, Adam G, Ciofu O, et al. Immunisation in the current management of cystic fibrosis patients. J Cyst Fibros 2005; 4:77.</a></li><li><a class="nounderline abstract_t">ACIP Updates: Recommendations for Use of 20-Valent Pneumococcal Conjugate Vaccine in Children - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:1072.</a></li><li class="breakAll">Cystic Fibrosis Foundation. CF Foundation Strongly Supports COVID-19 Vaccine Recommendations for People Living With Cystic Fibrosis. 2021. Available at: https://www.cff.org/News/News-Archive/2021/CF-Foundation-Strongly-Supports-COVID-19-Vaccine-Recommendations-for-People-Living-With-Cystic-Fibrosis/ (Accessed on June 07, 2021).</li><li class="breakAll">Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP): COVID-19 ACIP Vaccine Recommendations. Available at: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html (Accessed on June 07, 2021).</li><li class="breakAll">Cystic Fibrosis Foundation: What You Need to Know: COVID-19 Vaccine Allocation. Available at: https://www.cff.org/Life-With-CF/Daily-Life/Germs-and-Staying-Healthy/CF-and-Coronavirus/What-You-Need-to-Know-COVID-19-Vaccine-Allocation/ (Accessed on June 07, 2021).</li><li class="breakAll">American Academy of Pediatrics: Nirsevimab frequently asked questions. Available at: https://www.aap.org/en/patient-care/respiratory-syncytial-virus-rsv-prevention/nirsevimab-frequently-asked-questions/ (Accessed on October 06, 2023).</li><li><a class="nounderline abstract_t">Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:920.</a></li><li><a class="nounderline abstract_t">Linnane B, Kiernan MG, O'Connell NH, et al. Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland. Multidiscip Respir Med 2015; 10:32.</a></li><li><a class="nounderline abstract_t">Groves HE, Jenkins L, Macfarlane M, et al. Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland. Pediatr Pulmonol 2016; 51:379.</a></li><li><a class="nounderline abstract_t">Robinson KA, Odelola OA, Saldanha IJ. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 2016; 7:CD007743.</a></li><li><a class="nounderline abstract_t">Fink AK, Graff G, Byington CL, et al. Palivizumab and Long-term Outcomes in Cystic Fibrosis. Pediatrics 2019; 144.</a></li><li><a class="nounderline abstract_t">Saiman L, Siegel JD, LiPuma JJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014; 35 Suppl 1:S1.</a></li><li><a class="nounderline abstract_t">Weinberger M. Airways reactivity in patients with CF. Clin Rev Allergy Immunol 2002; 23:77.</a></li><li><a class="nounderline abstract_t">Levine H, Cohen-Cymberknoh M, Klein N, et al. Reversible airway obstruction in cystic fibrosis: Common, but not associated with characteristics of asthma. J Cyst Fibros 2016; 15:652.</a></li><li><a class="nounderline abstract_t">Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37 Suppl 3:S225.</a></li><li><a class="nounderline abstract_t">Moss RB. Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis. Curr Opin Pulm Med 2010; 16:598.</a></li><li><a class="nounderline abstract_t">Eggleston PA, Rosenstein BJ, Stackhouse CM, et al. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991; 99:1088.</a></li><li><a class="nounderline abstract_t">König P, Gayer D, Barbero GJ, Shaffer J. Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. Pediatr Pulmonol 1995; 20:205.</a></li><li><a class="nounderline abstract_t">König P, Poehler J, Barbero GJ. A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatr Pulmonol 1998; 25:32.</a></li><li><a class="nounderline abstract_t">Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013; 187:680.</a></li><li><a class="nounderline abstract_t">Hordvik NL, Sammut PH, Judy CG, Colombo JL. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis. Pediatr Pulmonol 2002; 34:287.</a></li><li><a class="nounderline abstract_t">Smith S, Edwards CT. Long-acting inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev 2017; 12:CD012102.</a></li><li><a class="nounderline abstract_t">Smith S, Rowbotham NJ, Edwards CT. Short-acting inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev 2022; 6:CD013666.</a></li><li><a class="nounderline abstract_t">Ratjen F, Koker P, Geller DE, et al. Tiotropium Respimat in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials. J Cyst Fibros 2015; 14:608.</a></li><li><a class="nounderline abstract_t">Bradley JM, Koker P, Deng Q, et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PLoS One 2014; 9:e106195.</a></li><li><a class="nounderline abstract_t">Roesch EA, Nichols DP, Chmiel JF. Inflammation in cystic fibrosis: An update. Pediatr Pulmonol 2018; 53:S30.</a></li><li><a class="nounderline abstract_t">Chmiel JF, Konstan MW. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med 2007; 28:331.</a></li><li><a class="nounderline abstract_t">Mayer-Hamblett N, Retsch-Bogart G, Kloster M, et al. Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial. Am J Respir Crit Care Med 2018; 198:1177.</a></li><li><a class="nounderline abstract_t">Saiman L, Mayer-Hamblett N, Anstead M, et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatr Pulmonol 2012; 47:641.</a></li><li><a class="nounderline abstract_t">Nichols DP, Odem-Davis K, Cogen JD, et al. Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis. Am J Respir Crit Care Med 2020; 201:430.</a></li><li><a class="nounderline abstract_t">Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57:212.</a></li><li><a class="nounderline abstract_t">Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290:1749.</a></li><li><a class="nounderline abstract_t">Richter WJ, Nguyen JA, Wu AE, et al. Low rates of macrolide-resistant Mycobacterium avium complex in cystic fibrosis despite chronic azithromycin therapy. J Cyst Fibros 2021; 20:555.</a></li><li><a class="nounderline abstract_t">Binder AM, Adjemian J, Olivier KN, Prevots DR. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013; 188:807.</a></li><li><a class="nounderline abstract_t">Cogen JD, Onchiri F, Emerson J, et al. Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens. Ann Am Thorac Soc 2018; 15:702.</a></li><li><a class="nounderline abstract_t">Nichols DP, Happoldt CL, Bratcher PE, et al. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. J Cyst Fibros 2017; 16:358.</a></li><li><a class="nounderline abstract_t">Lang BJ, Aaron SD, Ferris W, et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2000; 162:2241.</a></li><li><a class="nounderline abstract_t">Nichols DP, Singh PK, Baines A, et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax 2022; 77:581.</a></li><li><a class="nounderline abstract_t">Nick JA, Moskowitz SM, Chmiel JF, et al. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc 2014; 11:342.</a></li><li><a class="nounderline abstract_t">Somayaji R, Russell R, Cogen JD, et al. Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis. Ann Am Thorac Soc 2019; 16:853.</a></li><li><a class="nounderline abstract_t">Cogen JD, Faino AV, Onchiri F, et al. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment. Ann Am Thorac Soc 2021; 18:266.</a></li><li><a class="nounderline abstract_t">VanDevanter DR, LiPuma JJ. The Pitfalls of Polypharmacy and Precision Medicine in Cystic Fibrosis. Ann Am Thorac Soc 2019; 16:819.</a></li><li><a class="nounderline abstract_t">Magaret AS, Salerno J, Deen JF, et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. J Cyst Fibros 2021; 20:e16.</a></li><li><a class="nounderline abstract_t">Saiman L, Mayer-Hamblett N, Campbell P, et al. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005; 172:1008.</a></li><li><a class="nounderline abstract_t">Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2012; 11:CD002203.</a></li><li><a class="nounderline abstract_t">Denis A, Touzet S, Diabaté L, et al. Quantifying Long-Term Changes in Lung Function and Exacerbations after Initiation of Azithromycin in Cystic Fibrosis. Ann Am Thorac Soc 2020; 17:195.</a></li><li><a class="nounderline abstract_t">Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010; 303:1707.</a></li><li><a class="nounderline abstract_t">Stick SM, Foti A, Ware RS, et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respir Med 2022; 10:776.</a></li><li><a class="nounderline abstract_t">Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004; 42:1915.</a></li><li><a class="nounderline abstract_t">Hoffmann N, Lee B, Hentzer M, et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob Agents Chemother 2007; 51:3677.</a></li><li><a class="nounderline abstract_t">Wagner T, Burns JL. Anti-inflammatory properties of macrolides. Pediatr Infect Dis J 2007; 26:75.</a></li><li><a class="nounderline abstract_t">Ratjen F, Saiman L, Mayer-Hamblett N, et al. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest 2012; 142:1259.</a></li><li><a class="nounderline abstract_t">Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database Syst Rev 2019; 9:CD001505.</a></li><li><a class="nounderline abstract_t">Arranz I, Martín-Suárez A, Lanao JM, et al. Population pharmacokinetics of high dose ibuprofen in cystic fibrosis. Arch Dis Child 2003; 88:1128.</a></li><li><a class="nounderline abstract_t">Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332:848.</a></li><li><a class="nounderline abstract_t">Lands LC, Milner R, Cantin AM, et al. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007; 151:249.</a></li><li><a class="nounderline abstract_t">Balfour-Lynn IM, Welch K, Smith S. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev 2019; 7:CD001915.</a></li><li><a class="nounderline abstract_t">Bisgaard H, Pedersen SS, Nielsen KG, et al. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection. Am J Respir Crit Care Med 1997; 156:1190.</a></li><li><a class="nounderline abstract_t">Nikolaizik WH, Schöni MH. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr 1996; 128:271.</a></li><li><a class="nounderline abstract_t">van Haren EH, Lammers JW, Festen J, et al. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med 1995; 89:209.</a></li><li><a class="nounderline abstract_t">Balfour-Lynn IM, Lees B, Hall P, et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 2006; 173:1356.</a></li><li><a class="nounderline abstract_t">Allen DB. Effects of inhaled steroids on growth, bone metabolism, and adrenal function. Adv Pediatr 2006; 53:101.</a></li><li><a class="nounderline abstract_t">De Boeck K, De Baets F, Malfroot A, et al. Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients? Eur J Pediatr 2007; 166:23.</a></li><li><a class="nounderline abstract_t">Auerbach HS, Williams M, Kirkpatrick JA, Colten HR. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; 2:686.</a></li><li><a class="nounderline abstract_t">Lai HC, FitzSimmons SC, Allen DB, et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med 2000; 342:851.</a></li><li><a class="nounderline abstract_t">Sivan Y, Arce P, Eigen H, et al. A double-blind, randomized study of sodium cromoglycate versus placebo in patients with cystic fibrosis and bronchial hyperreactivity. J Allergy Clin Immunol 1990; 85:649.</a></li><li><a class="nounderline abstract_t">Guevara JP, Ducharme FM, Keren R, et al. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst Rev 2006; :CD003558.</a></li><li><a class="nounderline abstract_t">Tam J, Nash EF, Ratjen F, et al. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev 2013; :CD007168.</a></li><li><a class="nounderline abstract_t">Conrad C, Lymp J, Thompson V, et al. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. J Cyst Fibros 2015; 14:219.</a></li><li><a class="nounderline abstract_t">Bozic M, Goss CH, Tirouvanziam RM, et al. Oral Glutathione and Growth in Cystic Fibrosis: A Multicenter, Randomized, Placebo-controlled, Double-blind Trial. J Pediatr Gastroenterol Nutr 2020; 71:771.</a></li><li><a class="nounderline abstract_t">Calabrese C, Tosco A, Abete P, et al. Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis. J Cyst Fibros 2015; 14:203.</a></li><li><a class="nounderline abstract_t">Freedman SD, Blanco PG, Zaman MM, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004; 350:560.</a></li><li><a class="nounderline abstract_t">López-Neyra A, Suárez L, Muñoz M, et al. Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: a randomized, multi-center, double-blind, placebo-controlled trial. Prostaglandins Leukot Essent Fatty Acids 2020; 162:102186.</a></li><li><a class="nounderline abstract_t">Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001; 32:356.</a></li><li><a class="nounderline abstract_t">Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34:91.</a></li><li><a class="nounderline abstract_t">Elborn JS, Prescott RJ, Stack BH, et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000; 55:355.</a></li><li><a class="nounderline abstract_t">Nir M, Lanng S, Johansen HK, Koch C. Long-term survival and nutritional data in patients with cystic fibrosis treated in a Danish centre. Thorax 1996; 51:1023.</a></li><li><a class="nounderline abstract_t">Breen L, Aswani N. Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev 2012; :CD002767.</a></li><li><a class="nounderline abstract_t">Flume PA, Strange C, Ye X, et al. Pneumothorax in cystic fibrosis. Chest 2005; 128:720.</a></li><li><a class="nounderline abstract_t">Flume PA, Yankaskas JR, Ebeling M, et al. Massive hemoptysis in cystic fibrosis. Chest 2005; 128:729.</a></li><li><a class="nounderline abstract_t">Garcia B, Flume PA. Pulmonary Complications of Cystic Fibrosis. Semin Respir Crit Care Med 2019; 40:804.</a></li><li><a class="nounderline abstract_t">Ramos KJ, Smith PJ, McKone EF, et al. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. J Cyst Fibros 2019; 18:321.</a></li><li><a class="nounderline abstract_t">Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182:298.</a></li><li><a class="nounderline abstract_t">Dusmet M, Winton TL, Kesten S, Maurer J. Previous intrapleural procedures do not adversely affect lung transplantation. J Heart Lung Transplant 1996; 15:249.</a></li><li><a class="nounderline abstract_t">Curtis HJ, Bourke SJ, Dark JH, Corris PA. Lung transplantation outcome in cystic fibrosis patients with previous pneumothorax. J Heart Lung Transplant 2005; 24:865.</a></li><li><a class="nounderline abstract_t">Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015; 34:1.</a></li><li><a class="nounderline abstract_t">Noppen M, Dhondt E, Mahler T, et al. Successful management of recurrent pneumothorax in cystic fibrosis by localized apical thoracoscopic talc poudrage. Chest 1994; 106:262.</a></li><li><a class="nounderline abstract_t">Bayomy OF, Ramos KJ, Hee Wai T, et al. Hemoptysis and the Risk for Lung Transplant or Death without Transplant in Individuals with Cystic Fibrosis in the United States. Ann Am Thorac Soc 2022; 19:1986.</a></li><li><a class="nounderline abstract_t">Mingora CM, Flume PA. Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series. Chest 2021; 160:1232.</a></li><li><a class="nounderline abstract_t">Semasinghe Bandaralage SP, Tay G, Hay K, et al. Outcomes of artery embolisation for cystic fibrosis patients with haemoptysis: a 20-year experience at a major Australian tertiary centre. Intern Med J 2021; 51:1526.</a></li><li><a class="nounderline abstract_t">Martin LN, Higgins L, Mohabir P, et al. Bronchial Artery Embolization for Hemoptysis in Cystic Fibrosis Patients: A 17-Year Review. J Vasc Interv Radiol 2020; 31:331.</a></li><li><a class="nounderline abstract_t">Al-Samkari H, Shin K, Cardoni L, et al. Antifibrinolytic Agents for Hemoptysis Management in Adults With Cystic Fibrosis. Chest 2019; 155:1226.</a></li><li><a class="nounderline abstract_t">Wand O, Guber E, Guber A, et al. Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial. Chest 2018; 154:1379.</a></li><li><a class="nounderline abstract_t">Moen CA, Burrell A, Dunning J. Does tranexamic acid stop haemoptysis? Interact Cardiovasc Thorac Surg 2013; 17:991.</a></li><li><a class="nounderline abstract_t">O'Connor KE, Goodwin DL, NeSmith A, et al. Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series. J Cyst Fibros 2021; 20:399.</a></li><li><a class="nounderline abstract_t">Patel EM, Swamy GK, Heine RP, et al. Medical and obstetric complications among pregnant women with cystic fibrosis. Am J Obstet Gynecol 2015; 212:98.e1.</a></li><li><a class="nounderline abstract_t">Ashcroft A, Chapman SJ, Mackillop L. The outcome of pregnancy in women with cystic fibrosis: a UK population-based descriptive study. BJOG 2020; 127:1696.</a></li><li><a class="nounderline abstract_t">Padoan RF, Quattrucci S, Amato A, et al. Perinatal outcomes in women with cystic fibrosis: Data from the Italian Cystic Fibrosis Registry. Acta Obstet Gynecol Scand 2021; 100:1439.</a></li><li><a class="nounderline abstract_t">Shteinberg M, Taylor-Cousar JL, Durieu I, Cohen-Cymberknoh M. Fertility and Pregnancy in Cystic Fibrosis. Chest 2021; 160:2051.</a></li><li><a class="nounderline abstract_t">Schmidt CN, Friedman AM, DiMango EA, et al. Trends in and Outcomes of Deliveries Complicated by Cystic Fibrosis. Obstet Gynecol 2022; 140:861.</a></li><li><a class="nounderline abstract_t">Schechter MS, Quittner AL, Konstan MW, et al. Long-term effects of pregnancy and motherhood on disease outcomes of women with cystic fibrosis. Ann Am Thorac Soc 2013; 10:213.</a></li><li><a class="nounderline abstract_t">Thorpe-Beeston JG, Madge S, Gyi K, et al. The outcome of pregnancies in women with cystic fibrosis--single centre experience 1998-2011. BJOG 2013; 120:354.</a></li><li><a class="nounderline abstract_t">Cheng EY, Goss CH, McKone EF, et al. Aggressive prenatal care results in successful fetal outcomes in CF women. J Cyst Fibros 2006; 5:85.</a></li><li><a class="nounderline abstract_t">Reynaud Q, Rousset Jablonski C, Poupon-Bourdy S, et al. Pregnancy outcome in women with cystic fibrosis and poor pulmonary function. J Cyst Fibros 2020; 19:80.</a></li><li><a class="nounderline abstract_t">Cohen-Cymberknoh M, Gindi Reiss B, Reiter J, et al. Baseline Cystic fibrosis disease severity has an adverse impact on pregnancy and infant outcomes, but does not impact disease progression. J Cyst Fibros 2021; 20:388.</a></li><li><a class="nounderline abstract_t">Tonelli MR, Aitken ML. Pregnancy in cystic fibrosis. Curr Opin Pulm Med 2007; 13:537.</a></li><li><a class="nounderline abstract_t">Ahluwalia M, Hoag JB, Hadeh A, et al. Cystic fibrosis and pregnancy in the modern era: a case control study. J Cyst Fibros 2014; 13:69.</a></li><li><a class="nounderline abstract_t">Kazmerski TM, Jain R, Lee M, Taylor-Cousar JL. Parenthood impacts short-term health outcomes in people with cystic fibrosis. J Cyst Fibros 2022; 21:662.</a></li><li><a class="nounderline abstract_t">Canny GJ. Pregnancy in patients with cystic fibrosis. CMAJ 1993; 149:805.</a></li><li><a class="nounderline abstract_t">Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J 2020; 55.</a></li><li class="breakAll">Cystic Fibrosis Foundation. Adult Clinical Care guidelines (2004; reviewed by CFF in 2019). Available at: https://www.cff.org/Care/Clinical-Care-Guidelines/Age-Specific-Clinical-Care-Guidelines/Adult-Care-Clinical-Care-Guidelines/ (Accessed on March 26, 2020).</li></ol></div><div id="topicVersionRevision">Topic 6372 Version 111.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34090606" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34996830" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : CFTR variants are associated with chronic bronchitis in smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34996830" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : CFTR variants are associated with chronic bronchitis in smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31882447" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9624062" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11529289" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Influence of neonatal screening and centralized treatment on long-term clinical outcome and survival of CF patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8202897" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hospital care for adults with cystic fibrosis: an overview and comparison between special cystic fibrosis clinics and general clinics using a patient questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12527598" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Factors influencing outcomes in cystic fibrosis: a center-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7842816" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8310295" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34091202" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35772339" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chest computed tomography improvement in patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: Early report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17761616" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27009033" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19914445" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36343646" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11684212" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12324668" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33735508" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Dornase alfa for cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21438174" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33619014" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Withdrawal of dornase alfa increases ventilation inhomogeneity in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29599187" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The in vitro effect of nebulised hypertonic saline on human bronchial epithelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421365" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mucus clearance and lung function in cystic fibrosis with hypertonic saline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421364" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32669217" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: Effect on mucociliary clearance and clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31178421" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35286860" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37319354" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Nebulised hypertonic saline for cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30409023" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRESIS). A Randomized, Double-Blind, Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21478216" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22198974" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28258928" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33715994" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33686652" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Timing of dornase alfa inhalation for cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19327189" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cystic fibrosis pulmonary guidelines: airway clearance therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19467161" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Airway-clearance therapy guidelines and implementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35594286" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of airway clearance therapies on mucociliary clearance in adults with cystic fibrosis: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37042825" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18304896" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Treatment compliance in children and adults with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893365" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Validation of an instrument measuring patient satisfaction with chest physiotherapy techniques in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30676656" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Airway clearance techniques for cystic fibrosis: an overview of Cochrane systematic reviews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32352564" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Oscillating devices for airway clearance in people with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34910295" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Autogenic drainage for airway clearance in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37144842" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36727723" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Active cycle of breathing technique for cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20836133" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-term comparative trial of two different physiotherapy techniques; postural drainage with percussion and autogenic drainage, in the treatment of cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9386661" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Long-term comparative trial of conventional postural drainage and percussion versus positive expiratory pressure physiotherapy in the treatment of cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23407019" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20146387" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Lessons learned from a randomized trial of airway secretion clearance techniques in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23542462" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Airway clearance research in CF: the 'perfect storm' of strong preference and effortful participation in long-term, non-blinded studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35943025" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Physical activity and exercise training in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10700685" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A randomized controlled trial of a 3-year home exercise program in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25002195" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Exercise programme in patients with cystic fibrosis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34735776" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effects of a Partially Supervised Conditioning Program in Cystic Fibrosis: An International Multicenter, Randomized Controlled Trial (ACTIVATE-CF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30846472" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effects of exercise and airway clearance (positive expiratory pressure) on mucus clearance in cystic fibrosis: a randomised crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35731672" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Exercise versus airway clearance techniques for people with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21752728" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Impact of the A (H1N1) pandemic influenza (season 2009-2010) on patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19605871" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15978534" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Immunisation in the current management of cystic fibrosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37768876" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : ACIP Updates: Recommendations for Use of 20-Valent Pneumococcal Conjugate Vaccine in Children - United States, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37768876" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : ACIP Updates: Recommendations for Use of 20-Valent Pneumococcal Conjugate Vaccine in Children - United States, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37768876" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : ACIP Updates: Recommendations for Use of 20-Valent Pneumococcal Conjugate Vaccine in Children - United States, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37768876" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : ACIP Updates: Recommendations for Use of 20-Valent Pneumococcal Conjugate Vaccine in Children - United States, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37768876" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : ACIP Updates: Recommendations for Use of 20-Valent Pneumococcal Conjugate Vaccine in Children - United States, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37616235" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26473032" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26808981" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27439110" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31239289" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Palivizumab and Long-term Outcomes in Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25025126" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Infection prevention and control guideline for cystic fibrosis: 2013 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12162108" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Airways reactivity in patients with CF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26826913" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Reversible airway obstruction in cystic fibrosis: Common, but not associated with characteristics of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12975753" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20720494" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2019162" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A controlled trial of long-term bronchodilator therapy in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8606849" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9475328" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23540878" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12205570" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29253920" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Long-acting inhaled bronchodilators for cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35749226" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Short-acting inhaled bronchodilators for cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25819269" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Tiotropium Respimat in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25188297" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Testing two different doses of tiotropium Respimat®in cystic fibrosis: phase 2 randomized trial results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29999593" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Inflammation in cystic fibrosis: An update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17467552" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Inflammation and anti-inflammatory therapies for cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29890086" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22684984" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31661302" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11867823" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14519709" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32950412" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Low rates of macrolide-resistant Mycobacterium avium complex in cystic fibrosis despite chronic azithromycin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23927602" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29474110" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28025037" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11112146" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34706982" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24476418" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30840835" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32810412" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35448933" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The Pitfalls of Polypharmacy and Precision Medicine in Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33246911" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16040785" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23152214" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Macrolide antibiotics for cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31604024" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Quantifying Long-Term Changes in Lung Function and Exacerbations after Initiation of Azithromycin in Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20442386" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35662406" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15131149" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620382" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17195710" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Anti-inflammatory properties of macrolides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22595153" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31499593" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14670788" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Population pharmacokinetics of high dose ibuprofen in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7503838" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Effect of high-dose ibuprofen in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17719932" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31271656" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Inhaled corticosteroids for cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9351621" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636828" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7746914" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16556691" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17089864" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Effects of inhaled steroids on growth, bone metabolism, and adrenal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16799799" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2863676" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10727589" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2107242" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : A double-blind, randomized study of sodium cromoglycate versus placebo in patients with cystic fibrosis and bronchial hyperreactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625584" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23852992" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25228446" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32960827" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Oral Glutathione and Growth in Cystic Fibrosis: A Multicenter, Randomized, Placebo-controlled, Double-blind Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25458463" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14762183" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Association of cystic fibrosis with abnormalities in fatty acid metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33038833" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: a randomized, multi-center, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11596160" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12112774" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770814" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8977604" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Long-term survival and nutritional data in patients with cystic fibrosis treated in a Danish centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22786481" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16100160" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Pneumothorax in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16100161" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Massive hemoptysis in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31659729" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Pulmonary Complications of Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30926322" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20675678" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8777207" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Previous intrapleural procedures do not adversely affect lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15982615" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Lung transplantation outcome in cystic fibrosis patients with previous pneumothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25085497" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8020281" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Successful management of recurrent pneumothorax in cystic fibrosis by localized apical thoracoscopic talc poudrage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35759341" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Hemoptysis and the Risk for Lung Transplant or Death without Transplant in Individuals with Cystic Fibrosis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34147501" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34541776" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Outcomes of artery embolisation for cystic fibrosis patients with haemoptysis: a 20-year experience at a major Australian tertiary centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31899109" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Bronchial Artery Embolization for Hemoptysis in Cystic Fibrosis Patients: A 17-Year Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30790551" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Antifibrinolytic Agents for Hemoptysis Management in Adults With Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30321510" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23966576" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Does tranexamic acid stop haemoptysis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33353860" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25025942" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Medical and obstetric complications among pregnant women with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32683738" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : The outcome of pregnancy in women with cystic fibrosis: a UK population-based descriptive study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34028004" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Perinatal outcomes in women with cystic fibrosis: Data from the Italian Cystic Fibrosis Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34284004" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Fertility and Pregnancy in Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36201759" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Trends in and Outcomes of Deliveries Complicated by Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23802817" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Long-term effects of pregnancy and motherhood on disease outcomes of women with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23145929" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : The outcome of pregnancies in women with cystic fibrosis--single centre experience 1998-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16650742" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Aggressive prenatal care results in successful fetal outcomes in CF women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31272894" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Pregnancy outcome in women with cystic fibrosis and poor pulmonary function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32917549" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Baseline Cystic fibrosis disease severity has an adverse impact on pregnancy and infant outcomes, but does not impact disease progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901761" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Pregnancy in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24018176" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Cystic fibrosis and pregnancy in the modern era: a case control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35181269" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Parenthood impacts short-term health outcomes in people with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8374842" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Pregnancy in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31699837" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
